DNA metüülimise roll kokaiini poolt põhjustatud käitumusliku sensitisatsiooni kujunemises by Anier, Kaili
K
A
IL
I A
N
IE
R
 
T
he role of D
N
A
 m
ethylation in the developm
ent of cocaine-induced behavioural sensitisation
Tartu 2013
ISSN 1736–2792
ISBN 978–9949–32–431–6
DISSERTATIONES 
NEUROSCIENTIAE
UNIVERSITATIS 
TARTUENSIS
19
KAILI ANIER
The role of DNA methylation 
in the development of cocaine-induced 
behavioural sensitisation
DISSERTATIONES NEUROSCIENTIAE UNIVERSITATIS TARTUENSIS 
19 
DISSERTATIONES NEUROSCIENTIAE UNIVERSITATIS TARTUENSIS 
19 
 
 
 
 
 
 
 
 
 
KAILI ANIER 
 
 
The role of DNA methylation  
in the development of cocaine-induced 
behavioural sensitisation  
 
 
 
 
 
 
 
 
 
 
 
Department of Pharmacology, Institute of Bio- and Translational Medicine, 
University of Tartu, Estonia 
 
Dissertation was accepted for the commencement of the degree of Doctor of 
Philosophy (Neurosciences) on October 8, 2013 by the Council of the 
Commencement of Doctoral Degree in Neuroscience 
 
Supervisors: Anti Kalda, MD, PhD, Senior Research Fellow,  
Department of Pharmacology, Institute of Bio- and 
Translational Medicine, University of Tartu 
 
Alexander Zharkovsky, MD, PhD, Professor,  
Department of Pharmacology, Institute of Bio- and 
Translational Medicine, University of Tartu 
 
Reviewers: Jaanus Harro, MD, PhD, Professor,  
Department of Psychophysiology, Institute of Psychology, 
University of Tartu 
   
 Anton Terasmaa, PhD, Senior Research Fellow,  
Department of Physiology, Institute of Bio- and  
Translational Medicine, University of Tartu  
 
Opponent: Markus Mikael Forsberg, PhD, Associate Professor,  
School of Pharmacy, University of Eastern Finland, Finland 
 
Commencement: December 19, 2013 
 
 
Publication of this dissertation is granted by the University of Tartu 
This research was supported by the European Regional Development Fund 
 
 
 
 
ISSN 1736–2792 
ISBN 978–9949–32–431–6 (print)  
ISBN 978–9949–32–432–3 (pdf)  
 
 
Copyright: Kaili Anier, 2013 
 
University of Tartu Press 
www.tyk.ee 
 
 
 
 
 
 
 
 
  
 
 
5 
CONTENTS 
ABBREVIATIONS ........................................................................................  9 
INTRODUCTION ..........................................................................................  12 
REVIEW OF THE LITERATURE ................................................................  14 
1.  Drug addiction and behavioural sensitisation ......................................  14 
2. Epigenetics and epigenetic mechanisms ..............................................  17 
2.1.  Histone modifications ...................................................................  19 
2.1.1. Histone acetylation and deacetylation ................................  19 
2.1.2.  Histone methylation ...........................................................  20 
2.1.3.  Histone phosphorylation ....................................................  20 
2.2.  DNA methylation and DNA methyltransferases ..........................  21 
2.2.1.  S-adenosylmethionine and DNA methylation ....................  22 
2.2.2.  DNA demethylation ...........................................................  23 
2.3.  microRNA ....................................................................................  24 
2.4.  Epigenome ....................................................................................  24 
2.5.  The role of epigenetic mechanisms in drug addiction ..................  25 
2.5.1.  Histone modifications in drug addiction ............................  25 
2.5.2.  DNA methylation and drug addiction ................................  26 
2.5.3.  microRNA and drug-related behaviour ..............................  27 
3.  The role of early-life stress  as a predictor of drug addiction...............  28 
3.1.  Maternal separation and drug addiction .......................................  30 
3.2.  Maternal separation and epigenetic modifications .......................  31 
AIMS OF THE STUDY .................................................................................  34 
MATERIALS AND METHODS ...................................................................  35 
1.  Animals and housing conditions (Papers I–III)....................................  35 
2.  Maternal separation and handling procedures  (Paper III) ...................  35 
3.  Drug administration (Papers I–III) .......................................................  36 
3.1.  Intracerebroventricular cannula implantation (Paper I) ................  36 
4.  Behavioural experiments ......................................................................  36 
4.1.  Locomotor activity measurement (Papers I–III) ..........................  36 
4.2.  Exploration box test (Paper III) ....................................................  37 
5.  Tissue isolation (Papers I–III) ..............................................................  38 
6.  PC12 cells and DNMT activity measurement (Paper II) .....................  38 
7.  Gene expression analyses .....................................................................  39 
7.1.  Measuring mRNA levels using qPCR (Papers I–III) ...................  39 
7.2.  Gene expression profiling (Paper II) ............................................  40 
8.  DNA methylation assays ......................................................................  40 
8.1.  Methylated DNA immunoprecipitation (Papers I–III) .................  40 
8.2.  Methylation-specific qPCR analysis (Papers I, III) ......................  41 
LIST OF ORIGINAL PUBLICATIONS .......................................................  8 
2
6 
8.3.  Primer sequences (Papers I–III) ...................................................  42 
9. Global DNA methylation analysis (Paper III) .......................................  43 
10. Chromatin immunoprecipitation assay (Paper I) .................................  43 
11. Western blotting (Papers I, III) ...........................................................  43 
12. Statistical analysis (Papers I–III) .........................................................  44 
RESULTS .......................................................................................................  45 
1.  The effect of DNA methylation on cocaine-induced  
behavioural sensitisation in mice (Paper I) ..........................................  45 
1.1.  Acute and repeated cocaine treatment increases  
locomotor activity in mice ............................................................  45 
1.2.  The effect of cocaine treatment on DNMT expression  
in the NAc and hippocampus .......................................................  45 
1.3.  Cocaine treatment alters the expression of selected genes  
in the NAc ....................................................................................  47 
1.4.  Cocaine treatment alters DNA methylation  
in the PP1c and fosB promoters ...................................................  49 
1.5.  The effect of the DNMT inhibitor zebularine on  
cocaine-induced DNA methylation and the development   
of behavioural sensitisation in mice .............................................  51 
2.  The effect of treatment with SAM on cocaine-induced  
DNA methylation and  behavioural sensitisation  
in mice (Paper II) .................................................................................  54 
2.1.  SAM pretreatment potentiates the development and  
expression of cocaine-induced behavioural  
sensitisation in mice .....................................................................  54 
2.2.  SAM modifies cocaine-induced gene expression .........................  55 
2.3.  SAM pretreatment alters cocaine-induced  
CpG-island methylation and transcriptional  
activity in the NAc .......................................................................  56 
2.4.  The effect of SAM treatment on methyltransferase  
activity and DNMT-expression in PC12 cells ..............................  59 
2.5.  SAM treatment hypermethylates the Dnmt3a promoter and 
downregulates mRNA levels in the NAc .....................................  60 
3.  The role of MS on DNA methylation and  
behavioural changes in rats (Paper III) ................................................  62 
3.1.  The effect of MS on exploratory behaviour and   
cocaine-induced behaviour ...........................................................  62 
3.2.  MS-induced DNMT upregulation is maintained  
into adulthood ...............................................................................  63 
3.3.  The effect of MS on global DNA methylation levels   
in the NAc and PFC ......................................................................  64 
3.4.  MS is associated with hypermethylation in the PP1c  
and  A2AR promoter regions in the NAc ........................................  65 
7 
DISCUSSION ................................................................................................  68 
1. The role of DNA methylation on cocaine-induced behavioural 
sensitisation in mice (Paper I) ..............................................................  68 
1.1. The role of DNMT on cocaine-induced behavioural  
sensitisation ..................................................................................  68 
1.2. DNA methylation regulates PP1c and fosB transcription   
in the NAc after acute and repeated cocaine treatment ................  69 
1.3. DNMT inhibition by zebularine delays the development   
of cocaine-induced behavioural sensitisation ...............................  70 
2. The role of SAM in cocaine-induced DNA methylation  
and behavioural sensitisation in mice (Paper II) ..................................  71 
2.1. The effect of SAM treatment on cocaine-induced gene  
expression and CpG-island methylation .......................................  71 
2.2. The effect of SAM on DNMT expression and   
methyltransferase activity .............................................................  73 
2.3. The effect of SAM treatment on cocaine-induced   
behavioural sensitisation ..............................................................  74 
3. The role of MS in DNA methylation and behavioural  
changes (Paper III) ...............................................................................  75 
3.1. The effect of MS on exploratory behaviour and   
cocaine-induced behaviour in adult rats .......................................  75 
3.2. The effect of MS on the expression of DNMT and   
selected genes ...............................................................................  76 
CONCLUSIONS ............................................................................................  78 
REFERENCES ...............................................................................................  79 
SUMMARY IN ESTONIAN .........................................................................  95 
ACKNOWLEDGEMENTS ...........................................................................  99 
PUBLICATIONS ...........................................................................................  101 
CURRICULUM VITAE ................................................................................  1  
 
 
45
8 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original research papers, which are 
referred to in the text by their Roman numerals.  
 
I Anier K, Malinovskaja K, Aonurm-Helm A, Zharkovsky A, Kalda A 
(2010) DNA methylation regulates cocaine-induced behavioral sensi-
tization in mice. Neuropsychopharmacology 35:2450–2461. 
 
II Anier K, Zharkovsky A, Kalda A (2013) S-adenosylmethionine modifies 
cocaine-induced DNA methylation and increases locomotor sensitization in 
mice. The International Journal of Neuropsychopharmacology 16:2053–
2066. 
 
III Anier K, Malinovskaja K, Pruus K, Aonurm-Helm A, Zharkovsky A, 
Kalda A (2013) Maternal separation is associated with DNA methylation 
and behavioural changes in adult rats. European Neuropsychophar-
macology [Epub ahead of print]. 
 
 
  
The contribution of the author to the original publications is as follows: 
 
I The author was the primary individual who performed the gene expression, 
DNA methylation and chromatin immunoprecipitation studies and who 
analysed the data and participated in the study design and manuscript 
writing. 
 
II The author was the primary individual who performed the gene expression, 
DNA methylation and cell culture studies and who analysed the data, 
participated in the study design, manuscript writing and handled 
correspondence. 
 
III The author performed all of the molecular biological experiments, with the 
exception of the Western blotting, and the author also analysed the data, 
wrote the manuscript and handled the correspondence. 
 
 
Published papers are reprinted with the permission of the copyright owners. 
 
 
9 
ABBREVIATIONS 
ABC avidin-biotin complex 
AC acute cocaine treatment 
ACTH adrenocorticotrophic hormone  
ADP adenosine diphosphate 
AFR animal-facility reared 
AID activation-induced cytidine deaminase 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA anaysis of variance 
APOBEC apolipoprotein B mRNA editing enzyme complex 
AP-1  activator protein-1 
A2AR adenosine A2A receptor 
5-aza 5-aza-2’-deoxycytidine 
Bdnf brain-derived neurotrophic factor 
bp  base pair 
cAMP  cyclic adenosine monophosphate 
CBP  CREB-binding protein 
Cck cholecystokinin 
Cdk5  cyclin-dependent kinase 5 
cDNA complementary DNA 
c-Fos  FBJ murine osteosarcoma viral oncogene 
ChIP  chromatin immunoprecipitation 
CNS central nervous system 
CpG  cytosine-guanine dinucleotide 
CPP conditioned place preference 
CRE cAMP response element 
CREB  cAMP response element binding protein 
CRF corticotrophin-releasing factor  
CT cycle threshold 
DARPP-32 cAMP-regulated phosphoprotein 32 kDa  
DAVID database for annotation, visualization and integrated discovery 
DNA  deoxyribonucleic acid 
DNMT  DNA methyltransferase 
ERK  extracellular signal-regulated kinase 
FC fold change 
fosB FBJ osteosarcoma oncogene B 
fra-1,2 fos-related antigen 1 and 2 
GABA γ-aminobutyric acid 
GADD45 growth arrest and DNA damage-inducible protein 45 
Gal galanin 
Gapdh glyceraldehyde-3-phosphate dehydrogenase 
GC glucocorticoid 
GEO gene expression omnibus 
 3
10 
GluR1 glutamate receptor 1 
GO gene ontology 
GR  glucocorticoid receptor 
G9a histone H3 lysine K9 methyltransferase 
HAT  histone acetyltransferase 
HDAC histone deacetylase 
HDM  histone demethylase 
5-hmc 5-hydroxymethylcytosine 
HMT  histone methyltransferase 
HPA hypothalamic-pituitary-adrenal axis 
5-HT serotonin 
i.c.v. intracerebroventricular 
i.p. intraperitoneal 
kb kilobase 
kDa kilo Dalton, the unified atomic mass unit 
LG licking and grooming 
LSD1 lysine specific demethylase 1 
MAPK  mitogen activated protein kinase 
MBD methyl-CpG-binding domain protein  
5-mC 5-methylcytosine 
MeC methylated cytosine 
MeCP2 methyl-CpG-binding protein 2 
MeDIP methylated DNA immunoprecipitation 
MET L-methionine 
mRNA  messenger ribonucleic acid 
MR mineralocorticoid receptor 
MS maternal separation 
MS15 15 min maternal separation 
MS180 180 min maternal separation 
MSK1  mitogen- and stress-activated protein kinase 1 
MSP qPCR methylation-specific quantitative polymerase chain reaction 
NAc  nucleus accumbens 
NH non-handled 
OD optical density 
PBS  phosphate buffered saline 
PC12 pheochromocytoma cells 
PFC prefrontal cortex 
PKA  protein kinase A 
PND postnatal day 
PP1 protein phosphatase 1 
PP1c protein phosphatase 1 catalytic subunit 
qPCR quantitative polymerase chain reaction 
Reln reelin 
RC repeated cocaine treatment 
11 
RG-108 non-nucleoside DNA methyltransferase inhibitor 
RNA  ribonucleic acid 
RST repeated SAM treatment 
SAH S-adenosylhomocysteine 
SAHA  suberoylanilide hydroxamic acid 
SAL saline 
SAM S-adenosylmethionine 
SDS sodium dodecyl sulfate 
SEM  standard error of mean 
Ser133 serine 133 
Slc17a7 solute carrier family 17 member 7 
SST single SAM treatment 
TBS TRIS buffered saline 
TET ten-eleven translocation enzyme 
Tris-EDTA trishydroxymethylaminomethane-Ethylenediaminetetraacetic acid 
TSA  trichostatin A  
VTA  ventral tegmental area 
ZEB zebularine 
ΔcJun  truncated form of cJun, dominant negative of ΔFosB 
ΔFosB  truncated form of FosB that is induced by chronic drug use 
12 
INTRODUCTION 
Drug addiction is a chronic relapsing disorder characterised by a pattern of 
compulsive drug seeking and taking behaviour despite severe adverse 
consequences (Kalivas et al., 2005; Hyman et al., 2006; Koob and Kreek, 
2007). Prolonged abuse of drugs, such as psychostimulants, may contribute to 
behavioural abnormalities that can last for months or even years after 
discontinuing drug consumption. Drug addiction is a multi-factorial and 
polygenic disorder that does not conform to a simple Mendelian transmission 
pattern (Goldman, 1993; Enoch and Goldman, 1999; Goldman et al., 2005; 
Wong et al., 2011). Individuals are differentially vulnerable to substance abuse, 
and not everyone who uses an addictive substance becomes addicted. Extensive 
epidemiological studies show that roughly half of an individual’s risk for drug 
addiction is genetic but the specific genes that confer a risk for drug addiction 
are not well known (Nestler, 2001; Goldman et al., 2005; Hyman et al., 2006), 
although several possible candidates have been proposed (Wang et al., 2012). 
Entrance into the addicted state clearly results from the interplay between an 
inherited predisposition (e.g., via genetic variants that mediate the personality 
traits associated with drug-seeking behaviour and dependence) and the 
environment (e.g., actual exposure to drugs of abuse) (Nestler, 2001; Goldman 
et al., 2005; Wong et al., 2011). There is evidence that suggests that stressful 
and traumatic experiences in early life also have a long-lasting impact on the 
behaviour of an individual. However, the mechanisms that mediate the effects 
of the early environment on this behaviour are not yet fully understood. Recent 
findings suggest that the epigenome, which comprises the machinery for 
programming long-term gene expression profiles and thus defines gene function 
and phenotype, can be modulated by a variety of environmental factors 
including nutrients, chemicals and the early-life environment (Weaver et al., 
2004; Waterland et al., 2006; Roth et al., 2009; Szyf, 2009). Therefore, the 
epigenome provides an important interface between genes and the environment 
and may be viewed as a potential mechanism underlying the rapid form of 
environmentally driven adaptation (Franklin and Mansuy, 2010).  
Repeated administration of psychostimulants (such as cocaine) induces an 
enhanced behavioural response to subsequent drug exposure, a phenomenon 
known as psychomotor or behavioural sensitisation (Robinson and Berridge, 
1993; Pierce and Kalivas, 1997). Psychostimulant-induced behavioral 
sensitisation in rodents provides a model of these addictive behaviours (such as 
those associated with craving and relapse) and the psychotic complications of 
psychostimulant abuse (Robinson and Becker, 1986). Behavioural sensitisation 
is remarkably persistent phenomenon. In rodents, it can persist from months to 
years after drug treatment is discontinued. Persistent behavioural sensitisation 
indicates that drug-induced short- and long-term changes in gene expression 
may be involved. Accumulating data suggest that epigenetic mechanisms (such 
as DNA methylation, histone modifications and microRNAs) contribute to 
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drug-induced transcriptional and behavioural changes (Kumar et al., 2005; 
Levine et al., 2005; Renthal et al., 2007; Wang et al., 2010). 
The general aim of this study was to investigate the role of DNA methylation 
in the development of cocaine-induced behavioural sensitisation in mice and 
rats. The more specific aims were: a) to determine the role of cocaine treatment 
on the expression of DNA methyltransferases (DNMTs) and selected genes in 
the nucleus accumbens (NAc) of mice and to assess the effect of the DNMT 
inhibitor zebularine on the development of behavioural sensitisation in mice; b) 
to investigate the role of the methyl donor S-adenosylmethionine (SAM) on 
cocaine-induced gene expression changes and the development of behavioural 
sensitisation in mice; c) using maternal separation (MS) as an early-life stress 
model, to evaluate whether MS in rats could alter cocaine-induced behavioural 
sensitisation in adulthood via aberrant DNA methylation. 
 4
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REVIEW OF THE LITERATURE 
1. Drug addiction and behavioural sensitisation 
Drug addiction can be defined as the loss of control of drug use or the 
compulsive seeking and taking of drugs despite adverse consequences (Nestler, 
2001). Once a person becomes addicted to drugs of abuse, only a few effective 
therapies can be used. Therefore, understanding the neural mechanisms that 
underlie the transition from recreational drug use to a chronically addicted state, 
and the mechanisms responsible for the persistence of addictive behaviours 
even after prolonged drug abstinence would provide clues as to how to block or 
reverse the addicted state and thereby diminish the rate of relapse (for a review 
see Renthal and Nestler, 2008). 
Psychostimulants, such as cocaine and amphetamine, change neuronal 
structure and function in specific brain regions, resulting in persistent changes 
at the molecular, cellular systems and behavioural levels (Paulson et al., 1991; 
Koob and LeMoal, 2001; Nestler, 2001; McQuown and Wood, 2010). Repeated 
administration of psychostimulants induces an enhanced behavioural response 
to subsequent drug exposure, a phenomenon known as psychomotor or 
behavioural sensitisation, that can persist for months (Robinson and Berridge, 
1993; Pierce and Kalivas, 1997). Behavioural sensitisation can be separated into 
two components – induction and expression of sensitisation. Induction of 
sensitisation refers to the progressive increase in locomotor activity during the 
repeated drug treatments. Expression of sensitisation is demonstrated following 
challenge with a low dose of psychostimulant after a drug-free period 
(McQuown and Wood, 2010). Psychostimulant-induced behavioural sensi-
tisation in rodents provides a model for addictive behaviours, such as those 
associated with craving and relapse, and for the psychotic complications of 
psychostimulant abuse (Koob and Bloom, 1988; Robinson and Berridge, 1993; 
Chen et al., 2003).  
Several neuropharmacological studies have indicated that drugs of abuse 
activate the brain reward circuitry, which centres on the dopaminergic neurons 
of the ventral tegmental area (VTA) of the midbrain and their projections to the 
limbic system – in particular, the NAc and regions of the prefrontal cortex 
(PFC) (Figure 1) (Kalivas and Volkow, 2005; Koob and LeMoal, 2005; Hyman 
et al., 2006; Robinson and Nestler, 2011). Under normal conditions, this reward 
circuitry controls an individual's responses to natural rewards, such as food, sex, 
play and social interactions. Compared with the natural rewards, drugs of abuse 
activate this reward circuitry far more strongly and persistently and without an 
association with productive behavioural outcomes. Chronic exposure to drugs 
modulates the described brain reward regions in part via homeostatic 
desensitisation that renders the individual unable to attain sufficient feelings of 
reward in the absence of drug (for a review see Robinson and Nestler, 2011).  
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Figure 1. Dopaminergic afferents in the brain that originate in the ventral tegmental 
area (VTA) and release dopamine in the nucleus accumbens (NAc) and other limbic 
targets. Thalamus (Thal), prefrontal cortex (PFC; modified from Robinson and Nestler, 
2011). 
 
The addictive phenotype may persists for the length of an individual’s life with 
drug craving and relapse occurring after weeks, months or even years of 
abstinence. This persistence suggests that drugs of abuse induce long-lasting 
changes in the brain that underlie the addiction behaviours (Robinson and 
Nestler, 2011). Therefore, it has been hypothesized that persistent alterations in 
gene expression could be responsible for the long-term behavioural and 
structural changes (Nestler and Aghajanian, 1997). 
The classic mechanism of gene expression regulation involves the actions of 
transcription factors, which are proteins that, in response to cell signaling 
pathways, bind specific DNA sequences in promoter regions of target genes and 
increase or decrease gene expression by promoting or blocking the recruitment 
of the RNA polymerase-II transcriptional complex (Robinson and Nestler, 
2011). It has been proposed that drugs of abuse activate certain transcription 
factors and thereby cause adaptive changes in neuronal structure and function 
(Kalivas et al., 2003). Although several different transcription factors exist, two 
of the most well known and best characterised transcription factors (associated 
with drug addiction) are cyclic adenosine monophosphate (cAMP) response 
element-binding protein (CREB) and ΔFosB (Nestler et al., 2001; McClung and 
Nestler, 2003).  
Phosphorylation of CREB by protein kinase A (PKA) at serine133 (Ser133) 
is an important event in the activation of CREB and cAMP response element 
(CRE)-dependent gene expression. Furthermore, phosphorylation of CREB at 
Ser133 allows recruitment of the transcriptional coactivator, CREB-binding 
protein (CBP), that in turn promotes transcription (Carlezon et al., 2005; Briand 
and Blendy, 2010; Robinson and Nestler, 2011). Psychostimulants and opiates 
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upregulate the cAMP pathway and thereby increase CREB activity in multiple 
brain regions including the NAc and dorsal striatum (Carlezon et al., 2005; 
Edwards et al., 2007; Briand and Blendy, 2010). Studies involving the inducible 
overexpression of CREB or a dominant negative mutant in bitransgenic mice or 
using viral vectors have demonstrated that CREB induction in the NAc 
decreases the rewarding effects of cocaine and opiates (Carlezon et al., 1998; 
Barrot et al., 2002; Robinson and Nestler, 2011). Data from Walters and Blendy 
(2001) demonstrated that mice partially deficient in CREB (CREBα, Δ mutant 
mice lack the α and Δ isoforms of CREB) showed an enhanced response to the 
reinforcing properties of cocaine compared with wild-type controls in both 
conditioned place preference (CPP) and sensitisation behaviours (Walters and 
Blendy, 2001). These results suggest that drug-induced CREB activation/ 
phosphorylation in the NAc comprises a negative feedback mechanism that 
dampens behavioural sensitivity to subsequent drug exposure (Carlezon et al., 
2005; Chen et al., 2009). However, temporally, CREB is induced rapidly after 
each drug treatment (effects are relatively short-lived) and returns to baseline 
after a few hours (Nestler, 2008). 
The transcription factor ΔFosB (encoded by the fosB gene) is a member of 
the Fos family, which comprises c-fos, fosb, fra-1 and fra-2 genes (Nestler et 
al., 2001; Nestler, 2008). ΔFosB heterodimerises with Jun family proteins  
(c-Jun, JunB, JunD) to form activator protein-1 (AP-1; known as transcription 
factor AP-1) complexes that bind to AP-1 sites in responsive genes to regulate 
transcription (Curran and Franza, 1988; Jorissen et al., 2007; Nestler, 2008). It 
has been found that acute exposure to drugs of abuse causes a transient increase 
in members of the Fos family of transcription factors (including c-fos, fosB) in 
the NAc and dorsal striatum (Nestler et al., 2001). During repeated exposures to 
drug of abuse, the expression of transcription factor ΔFosB increases several 
fold and often persists long after drug exposure ceases. Thus, ΔFosB 
extraordinary stability in neurons has led to the theory that it plays an important 
role in the onset of drug addiction (Bowers et al., 2004; McClung et al., 2004; 
Kalivas and O’Brien, 2008). Indeed, several previous studies have demonstrated 
that ΔFosB is directly associated with addiction-related behaviours. It has been 
found that prolonged ΔFosB expression in the NAc increases the rewarding 
effects of cocaine. For example, mice overexpressing ΔFosB demonstrated 
increased CPP, self-administration and incentive motivation for cocaine (Kelz 
et al., 1999; Nestler, 2001; Colby et al., 2003; Peakman et al., 2003). However, 
mice that express a dominant-negative form of cJun (ΔcJun), which disrupts 
normal AP-1 function, demonstrated less preference for cocaine (Nestler, 2008). 
Thus, to summarize, it appears that gene expression induced by short-term 
ΔFosB and by CREB reduces the rewarding effects of cocaine whereas 
prolonged ΔFosB expression increases drug reward. Furthermore, it has been 
demonstrated that gene expression after a short cocaine exposure was dependent 
on CREB whereas gene expression after a longer cocaine treatment was ΔFosB 
dependent (McClung and Nestler, 2003; Nestler, 2008).  
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Moreover, alterations in expression of Ags3 (activator of G protein signaling 
3) (Bowers et al., 2004) and Bdnf (brain-derived neurotrophic factor) (Grimm et 
al., 2003) has been reported weeks after the last drug experience (Renthal and 
Nestler, 2008). Manipulation of these genes in rodents regulates drug relapse 
behaviour (Bowers et al., 2004; Lu et al., 2004; Graham et al., 2007; Renthal 
and Nestler, 2008). A multitude of microarray studies under different 
experimental conditions have identified several potential target genes for drugs 
of abuse in distinct brain reward regions that may promote their long-lasting 
behavioural effects (Freeman et al., 2001; McClung and Nestler, 2003; Yuferov 
et al., 2003; Yao et al., 2004; McClung et al., 2005; Winstanley et al., 2007; 
LaPlant and Nestler, 2011). Several recent reports suggest that epigenetic 
mechanisms – key cellular processes that transform diverse environmental 
stimuli into long-lasting changes in gene expression via the regulation of 
chromatin structure – contribute to drug-induced transcriptional and behavioural 
changes (Kumar et al., 2005; Levine et al., 2005; Renthal et al., 2007; Renthal 
and Nestler, 2008; Wang et al., 2010). 
 
 
2. Epigenetics and epigenetic mechanisms 
The sequence of nucleotides comprising an individual’s genome is identical, 
with the exception of a few rare somatic mutations, across all cells in the body. 
Every cell in our bodies contains the same DNA sequence and each cell has its 
own unique phenotype characterised by a specific pattern of gene expression 
that is in a constant state of flux. In the context of determining the phenotype of 
a cell, it is also important the degree to which specific genes are functionally 
active at any particular time in development. Therefore, sequencing the genome 
was only the first step in our quest to understand how genes are expressed and 
regulated (for a review see Smith and Mill, 2011; Wong et al., 2011). 
Accumulating evidence indicates that above the DNA sequence is a second 
layer of information – the epigenome – that regulates when and where genes are 
turned on or off. Historically, the term epigenetics (literally meaning “above 
genetics”) was coined by Conrad Hal Waddington in 1942 to describe the 
examination of causal mechanisms whereby the genes of the genotype bring 
about phenotypic effects (Haig, 2004; McQuown and Wood, 2010). Currently, 
epigenetics can be defined as long-lived and reversible modifications to 
nucleotides or chromosomes that do not change the sequence but can alter gene 
expression and phenotype (LaSalle et al., 2013). Epigenetic mechanisms are 
essential for normal cellular development and differentiation and allow the 
long-term regulation of gene function through non-mutagenic mechanisms 
(Smith and Mill, 2011). Several data suggest that alterations of epigenetic 
mechanisms affect the vast majority of nuclear processes (including gene 
transcription and silencing), DNA replication and repair, cell cycle, telomere 
and centromere function and structure (Gonzalo, 2010). During the last decade, 
the field of epigenetics has developed into one of the most influential areas of 
5 
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scientific research and has become an important topic in several neurobiology 
fields, such as learning and memory, psychiatric and neurological disorders. 
Epigenetics is used to refer to the extremely complex processes of 
organizing the genome in a manner that allows regulated gene expression in the 
appropriate cell type upon the appropriate cellular stimuli (LaPlant and Nestler, 
2011). The fundamental unit that accomplishes this feat on a molecular level is 
the chromatin, which is the complex of DNA, histones and non-histone proteins 
in the cell nucleus. The basic repeating structural unit of the chromatin is the 
nucleosome (Figure 2), which comprises ~147 base pairs (bp) of DNA wrapped 
around a core nucleosome (Strahl and Allis, 2000). Nucleosomes are composed 
of octamers that contain four histone homodimers, one of each of the histones 
H2A, H2B, H3 and H4, with H1 binding to spans of non-nucleosomal DNA 
(Robinson and Nestler, 2011). The histone-DNA configuration is maintained by 
electrostatic bonds between the positively charged histones and the negatively 
charged DNA (Grunstein, 1997). This highly condensed histone proteins-DNA 
complex structure means that control over gene expression occurs in part by 
gating access of transcriptional activators to DNA (Felsenfeld and Groudine, 
2003; Li et al., 2007; Renthal and Nestler, 2008).  
 
 
Figure 2. DNA is wrapped around a cluster of histone proteins to form nucleosomes. 
During histone modifications, a combination of different molecules can attach to the 
tails of histones, which consequently change the state of the chromatin around the DNA. 
When the chromatin open, the transcription of associated genes is activated with the 
opposite being true when chromatin close. During DNA methylation, methyl marks 
added to cytosine-guanine dinucleotide (CpG) islands generally repress gene 
transcription (Wong et al., 2011). 
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The structure of chromatin and access to the DNA sequence wrapped around it 
is regulated by posttranslational modifications of histones and the DNA itself 
(Kouzarides, 2007). Numerous types of posttranslational modifications, such as 
acetylation, methylation, phosphorylation, ubiquitination and sumoylation of 
the amino (N)-terminal tails of histones alter chromatin compaction to create 
more open states (euchromatin, transcriptionally active) versus closed states 
(heterochromatin, transcriptionally inactive) (Cheung et al., 2000; Berger, 2007; 
Kouzarides, 2007; Robinson and Nestler, 2011). It has been found that histone 
modifications that weaken or disrupt histone-DNA contacts, such as histone 
acetylation, correlate with transcriptionally active states. In contrast, histone 
modifications that increase histone-DNA contacts, such as histone methylation 
at certain basic amino acid residues, promote transcriptional repression (Strahl 
and Allis, 2000; Maze and Nestler, 2011). Combinations of numerous 
posttranslational modifications on amino (N)-terminal histone tails have been 
shown to affect chromatin condensation and result in altered levels of gene 
expression in cells (Jenuwein and Allis, 2001; Maze and Nestler, 2011).  
 
 
2.1. Histone modifications 
Each histone protein comprises a central globular domain and an amino  
(N)-terminal tail that contains multiple sites for posttranslational modifications 
including acetylation, phosphorylation, methylation, ubiquitination, and ADP-
ribosylation. Most histone posttranslational modifications are dynamic (Allis et 
al., 2007; Berger, 2007; Kouzarides, 2007) and are regulated by a large number 
of histone modifying enzymes, such as acetyltransferases, deacetylases, 
methyltransferases, demethylases and kinases among others (Gibney and Nolan, 
2010).   
 
2.1.1. Histone acetylation and deacetylation 
The enzymes that regulate histone acetylation levels are histone acetyl-
transferases (HATs). The primary function of HATs is to neutralize the charges 
on histones to relax chromatin structure, which allows greater access of 
transcription factors to the DNA and thereby increases transcription (Norton et 
al., 1989; Barrett and Wood, 2008). In contrast, histone deacetylases (HDACs) 
deacetylate histone tails, and histone deacetylation has been linked to 
transcriptional repression (Kuo and Allis, 1998; Jenuwein and Allis, 2001; 
Narlikar et al., 2002). The HDAC family consists of a number of proteins that 
have a catalytic deacetylase domain and are divided into 4 classes. Class I 
HDACs (HDAC 1, 2, 3 and 8) are expressed ubiquitously and likely mediate the 
majority of deacetylase activity within cells. Class II HDACs (HDAC 4–7 and 
9–10) are larger proteins containing a deacetylase domain and an N-terminal 
regulatory domain that enables them to be shuttled in and out of the nucleus in a 
neural activity-dependent manner, and they enriched in specific tissues, such as 
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the brain and heart (Chawla et al., 2003; Renthal and Nestler, 2008). Class III 
HDACs are homologs of silent information regulator 2 (Sir2) and sirtuins, and 
HDAC11 is a class IV HDAC and shares homology with class I and II enzymes 
(Yang and Seto, 2008). The balance between the opposing activities of HATs 
and HDACs determines gene expression levels.  
 
2.1.2. Histone methylation  
Another group of important enzymes are histone methyltransferases (HMTs, 
such as SET, MLL and SUV39 among others), which are methylated at lysine 
(K) or arginine (R) residues and removed by histone demethylases (HDMs) 
(Tachibana et al., 2001; Hake et al., 2004; Shi et al., 2004). Histone methylation 
has been associated with both transcriptional activation and repression 
depending on the particular residue and the extent of methylation (Su and 
Tarakhovsky, 2006; Maze and Nestler, 2011). Lysine side chains may be  
mono-, di- or trimethylated whereas the arginine side chain may be mono- or 
dimethylated. Currently, there are 24 known methylation sites on histones – 17 
are lysine and 7 are arginine residues (Bannister and Kouzarides, 2005). It has 
been found that trimethylation of histone H3 lysines K4 (H3K4me3) and K36 
(H3K36me3) are highly associated with transcriptional initiation and often 
correlate with increased levels of transcriptional activity whereas di- and 
trimethylation of the histone H3 lysines K9 (H3K9me2/3) and K27 
(H3K27me2/3) is associated with transcriptional repression (Rice and Allis, 
2001; Maze and Nestler, 2011). Histone methylation is dynamically regulated 
by HMTs and HDMs. The first discovered HDM was lysine specific 
demethylase 1 (LSD1). LSD1 is flavin-dependent monoamine oxidase that 
demethylates mono- and dimethylated lysines, specifically histone H3 lysines 
K4 and K9 (H3K4 and H3K9). The Jumonji domain-containing (JmjC) histone 
demethylases (such as JHDM1 and JHDM2 – JmjC domain-containing histone 
demethylase 1 and 2, respectively) were discovered because lysines can be 
mono-, di-, and trimethylated and LSD1 only mediates mono- and dide-
methylation. They can demethylate mono-, di-, or trimethylated lysines and 
enable greater functional control of lysine methylation (Shi and Whetstine, 
2007).  
 
2.1.3. Histone phosphorylation 
Histone phosphorylation has been shown to be involved in a variety of cellular 
processes including transcriptional regulation, apoptosis, cell cycle progression, 
DNA repair and chromosome condensation (Banerjee and Chakravarti, 2011). 
The most described histone phosphorylation site is serine 10 on histone H3 
(H3S10). It has been found that this modification stabilizes a HAT (Gcn5) on 
gene promoters and antagonizes the methylation of lysine K9 on histone H3 
(H3K9) and the recruitment of heterochromatin protein 1 (HP1) (Kouzarides, 
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2007; Renthal and Nestler, 2008). Phosphorylation of serine or threonine 
residues on histone tails can be accomplished by nuclear kinases, such as 
mitogen- and stress-activated protein kinase (MSK-1), and dephosphorylation 
can be mediated by protein phosphatases (such as protein phosphatase 1, PP1) 
(Brami-Cherrier et al., 2009; Koshibu et al., 2009; Day and Sweatt, 2011). The 
exact mechanism by which phosphorylation contributes to transcriptional 
activation is not well understood but it is hypothesized that the addition of 
negatively charged phosphate groups to histone tails neutralizes the positive 
charge of histone tails and reduces their affinity for DNA (Grant, 2001; 
Tambaro et al., 2010).  
 
 
2.2. DNA methylation and DNA methyltransferases  
DNA methylation represents another important and unique epigenetic 
mechanism. The methylation of one of the four DNA bases, cytosine, is a 
relatively stable epigenetic modification that regulate the transcriptional 
plasticity of mammalian genomes. During DNA methylation, a methyl group is 
added to the 5′ position on the cytosine pyrimidine ring, occurring primarily 
where a cytosine (C) is next to guanine (G) in the DNA sequence (C-phosphate 
link-G or cytosine-guanine dinucleotides, CpG) (Holliday and Pugh, 1975; 
Klose and Bird, 2006; Wong et al., 2011). The CpG sequences are not evenly 
dispersed throughout the genome but are clustered in so-called CpG islands – 
short regions of 0.5 to 4 kb in length with a rich (60–70%) cytosine-guanine 
content. Over 50–60% of all dinucleotides in these islands are CpG, compared 
with the rest of the genome where the CpG content is ≤ 20% (Bird, 2002). 
Approximately 50% of CpG islands are located in promoter regions and around 
the transcription start sites and are unmethylated in normal cells (Robertson and 
Wolffe, 2000; Jones and Baylin, 2002). 
DNA methylation is generally considered to suppress gene transcription by 
recruiting co-repressor complexes (e.g., HDACs and HMTs) that can modify 
nucleosome structure (Robinson and Nestler, 2011). These complexes involve 
several DNA methyl-CpG-binding domain proteins (MBD; in mammals they 
are MeCP2, MBD1-4) that are necessary for normal cell growth and develop-
ment (Robertson and Wolffe, 2000; Chahrour and Zoghbi, 2007; Kim et al., 
2009). It should be noted that mechanistically, MeCP2 may act as both an 
activator and repressor of gene transcription (Chahrour et al., 2008).  
The methylation of cytosine is catalysed by DNA methyltransferases 
(DNMTs). In mammalian genomes, DNMTs are enzymes that have been 
demonstrated to mediate the transfer of a methyl group from S-adeno-
sylmethionine (SAM or AdoMet) to cytosine (Figure 3) (Eden et al., 2003; 
Villar-Garea et al., 2003; Goll and Bestor, 2005).  
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Figure 3. Modification of DNA by methylation at the 5-carbon position of cytosine by 
DNA methyltransferases (DNMTs) where S-adenosylmethionine (SAM) is the methyl 
group donor (−CH3) and which is converted to S-adenosylhomocysteine (SAH; 
modified from Wong et al., 2011). 
 
There are two main DNMT enzyme groups: DNMT1 and DNMT3 families. 
DNMT1, the first-identified eukaryotic DNMT, is essential for maintaining 
DNA methylation patterns in proliferating cells as they copy DNA methylation 
patterns from the matrix chain to newly synthesized DNA chain. It is also 
involved in establishing new DNA methylation patterns (de novo methylation) 
(Bestor, 2000; Goll and Bestor, 2005; Siedlecki and Zielenkiewicz, 2006). The 
DNMT3 family includes two active de novo DNMTs – DNMT3A and 
DNMT3B, which are necessary for establishing new DNA methylation patterns 
(Okano et al., 1999) – and one regulatory factor, DNMT3-Like protein 
(DNMT3L) (Bestor, 2000; Goll and Bestor, 2005). DNMT3L has not been 
shown to possess methyltransferase activity (Bourc’his et al., 2001) but 
regulates DNMT3A and DNMT3B by stimulating their catalytic activity 
(Cheng and Blumenthal, 2008). Organisms that contain members of the 
DNMT1 and DNMT3 families also have DNMT2, which displays weak DNMT 
activity (Okano et al., 1998; Yoder and Bestor, 1998; Siedlecki and Zielen-
kiewicz, 2006).  
 
2.2.1. S-adenosylmethionine and DNA methylation 
S-adenosylmethionine (SAM or AdoMet), first discovered in 1952, is formed 
from the essential amino acid methionine and adenosine triphosphate. SAM is 
the methyl group donor of multiple methylation reactions in all organisms 
(Chiang et al., 1996; Lu, 2000; Cheng and Roberts, 2001; Bottiglieri, 2002), 
whereas S-adenosylhomocysteine (SAH) is the product of transmethylation 
reactions and a DNMT inhibitor (Chiang, 1998; Detich et al., 2003). Studies 
have revealed that administration of exogenous SAM increases the intracellular 
ratio of SAM to SAH (Garcea et al., 1989; Pascale et al., 2002; Detich et al., 
2003). An increase in SAH concentration, even without a concomitant reduction 
in SAM, results in DNMT inhibition and DNA hypomethylation (Caudill et al., 
2001). For that reason, the SAM/SAH ratio has been proposed as a 
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“methylation index” that indicates the likelihood of hyper- or hypomethylation 
of DNA (Waterland, 2006).  
Several studies have suggested that exogenous SAM administration can 
increase the levels of intracellular SAM and trigger hypermethylation of DNA 
(Watson et al. 1999; Lu, 2000; Fuso et al. 2001), whereas methyl-deficient diets 
decrease intracellular SAM concentration, increase SAH concentrations and 
trigger DNA hypomethylation (Pogribny et al., 1995; Steinmetz et al., 1998; 
Poirier, 2002). It has been found that dietary supplements, such as SAM,  
L-methionine (MET) and folic acid, increases DNA methylation thereby 
altering gene expression (Ross, 2003). SAM has been used as a dietary 
supplement in Italy (since 1979), Spain (since 1985), Germany (since 1989), in 
the United States (since 1999) and in several other countries (Bottiglieri, 2002).  
 
2.2.2. DNA demethylation  
In contrast to the large amount of information that has accumulated on DNA 
methylation, DNA demethylation remains a quite controversial and largely 
unresolved area of research (Kapoor et al., 2005; Wu et al., 2010). DNA 
demethylation occurs via a series of chemical reactions that modify  
5-methylcytosine (5-mC) at two sites, the amino group and the methyl group. 
An alternative model for DNA demethylation involves the conversion of 
methylated cytosine (MeC) in DNA to thymine by deamination or loss of the 
amine group followed by conventional base and nucleotide excision repair 
processes that resynthesize a nonmethylated cytosine (Figure 4) (Ma et al., 
2009a; Day and Sweatt, 2010).  
 
 
Figure 4. Methylated DNA is deaminated and converted to thymine, and base or 
nucleotide excision repair processes replace the thymine with unmethylated cytosine. 
MeC-methylated cytosine (adapted from Day and Sweatt, 2010).  
 
It is assumed that the Growth Arrest and DNA Damage-inducible protein 45 
(GADD45) family of proteins (specifically GADD45β) participate in each step 
of this process and thereby catalyse DNA demethylation (Ma et al., 2009b). 
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Furthermore, it appears that DNMTs may also participate in the deamination of 
methylated cytosine in a strand-specific manner (Métivier et al., 2008), giving 
them a role in both DNA methylation and demethylation processes. Although 
not clear how this model affects methylation status on the complementary DNA 
strand, this mechanism enables selective demethylation at specific sites in DNA 
allowing transient methylation, active demethylation and a route of entry for the 
nucleoside analog DNMT inhibitors into the DNA of non-dividing cells (Day 
and Sweatt, 2010). DNMT inhibitors, such as zebularine or 5-aza-2’-
deoxycytidine (5-aza), may operate by substituting for cytosine during base 
excision repair processes; this altered base is resistant to methylation and traps 
DNMTs, resulting in a decrease in DNMT activity and in the demethylation of 
the newly repaired strand (Szyf, 2009; Day and Sweatt, 2010). 
Another active DNA demethylation mechanism is mediated by the ten-
eleven translocation (TET) enzymes TET1-3, which add a hydroxyl group onto 
the methyl group of 5-methylcytosine (5-mC) to form 5-hydroxymethylcytosine 
(5-hmC) (Tahiliani et al., 2009; Ito et al., 2010). In mammals, once 5-hmC is 
formed, 2 separate mechanisms then convert 5-hmC back into cytosine. 
Initially, iterative oxidation by TET enzymes continue to oxidize 5-hmC to  
5-formylcytosine (5-fC) and then to 5-carboxycytosine (5-caC) (Ito et al., 
2011). Second, 5-hmC is deaminated by AID/APOBEC (activation-induced 
cytidine deaminase/apolipoprotein B mRNA editing enzyme complex) to form 
5-hydroxymethyl-uracil (5-hmU) (Guo et al., 2011; Moore et al., 2013). These 
data indicate that 5-hmC may also play a role in the process of active DNA 
demethylation.  
 
 
2.3. microRNA 
Another level of epigenetic regulation by small non-coding RNAs (termed 
microRNAs) has been discovered (Bergmann and Lane, 2003). MicroRNAs, 
which generally are approximately 22 bp long, are posttranslational regulators 
that bind to complementary sequences on target mRNAs and that regulate gene 
expression at different levels, i.e., chromatin silencing (affecting histone 
modifications), mRNA degradation and translation block (Szyf et al., 2008; Taft 
et al., 2010; Li and van der Vaart, 2011). Thus, as with histone modifications 
and DNA methylation, microRNAs are also important players in the epigenetic 
control of gene expression.  
 
 
2.4. Epigenome 
The pattern of epigenetic modifications in the genome, or the epigenome, is the 
result of a complex interplay between enzymes that modify DNA and histones, 
proteins that recognize these modifications and microRNAs (Bernstein et al., 
2007; Szyf, 2009; Telese et al., 2013). Thus, the epigenome comprises the 
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machinery that programmes long-term gene expression profiles that define gene 
function and phenotype and are expressed in behaviour (Szyf, 2009). Unlike the 
underlying genome, which is largely static within an individual, the epigenome 
can be dynamically altered by environmental factors, such as nutrients, 
chemicals and early life environment (Weaver et al., 2004; Waterland et al., 
2006; Szyf, 2009). Therefore, the epigenome provides an essential interface 
between genes and the environment and may be viewed as a potential mecha-
nism underlying the rapid form of environmentally driven adaptation (Franklin 
and Mansuy, 2010).  
 
 
2.5. The role of epigenetic mechanisms in drug addiction 
2.5.1. Histone modifications in drug addiction  
Drugs of abuse (e.g., cocaine, amphetamine, ethanol) induce changes in histone 
modifications in the brain, and evidence has begun to accumulate that these 
modifications are associated with some of the functional abnormalities found in 
addiction models (Kumar et al., 2005; Kim and Shukla, 2006; Kalda et al., 
2007; Robinson and Nestler, 2011). For example, it has been found that acute 
and chronic exposure to cocaine increases global levels of histone H3 and H4 
acetylation in the rodent NAc (Kumar et al., 2005). At the gene level, it has 
been shown that acute cocaine treatment was associated with histone H4 
hyperacetylation at the promoters of the immediate early genes, such as c-fos 
and fosB, whereas repeated cocaine treatment was associated with histone H3 
hyperacetylation at the Cdk5 and Bdnf promoters. 
Further studies have demonstrated that modifications in HDAC activity are 
substantial regulators of the rewarding properties of cocaine. Short-term 
systemic or intra-NAc administration of non-specific HDAC inhibitors prior to 
cocaine or morphine exposure enhances behavioural preferences for places 
associated with drug delivery (so-called CPP) (Kumar et al., 2005; Sanchis-
Segura et al., 2009; Robinson and Nestler, 2011). It has been found that 
overexpression of HDAC4 or HDAC5 reduces behavioural responses to cocaine 
(Kumar et al., 2005; Renthal et al., 2007), whereas genetic deletion of HDAC5 
hypersensitizes mice to the chronic effects (but not to the acute effects) of the 
drug (Renthal et al., 2007). It has also been demonstrated that mutant mice with 
decreased expression of CBP (a major HAT in brain), exhibit reduced 
sensitivity to chronic cocaine exposure (Levine et al., 2005; Robinson and 
Nestler, 2011). Moreover, chronic cocaine treatment increased expression of 
two sirtuins, Sirt1 and Sirt2, which are class III HDACs. Upregulation of sirtuin 
expression is associated with increased H3 acetylation and ΔFosB binding at 
Sirt1 and Sirt2 promoters, which indicates that sirtuins are downstream targets 
of ΔFosB (Robinson and Nestler, 2011). Pharmacological inhibition of sirtuins 
reduces CPP and cocaine self-administration, whereas activation increases 
rewarding responses to cocaine (Renthal et al., 2009). Despite the fact that a 
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single cocaine exposure does not itself alter sirtuin activity, upregulation after 
chronic cocaine exposure may mediate the stable neuroadaptive changes 
involved in maintaining addiction (McQuown and Wood, 2010).  
There is evidence that histone methylation is also directly regulated by drugs 
of abuse (Robinson and Nestler, 2011). The experiments by Maze and 
colleagues (2010) have demonstrated that global levels of histone H3 lysine K9 
dimethylation (H3K9me2) are decreased in the mouse NAc after chronic 
cocaine exposure (Maze et al., 2010). Genome-wide studies by Renthal et al. 
(2009) revealed alterations in H3K9me2 binding on numerous gene-promoter 
regions in the NAc. The global reduction in H3K9me2 in the NAc was 
mediated via the repression of G9a (known as HMT), which was regulated by 
the cocaine-induced transcription factor ΔFosB (Robinson and Nestler, 2011). It 
has been reported that acute cocaine exposure enhanced G9a binding in the fosB 
promoter region and therefore rapidly suppressed cocaine-induced increases in 
ΔFosB expression (Maze and Nestler, 2011). Following repeated cocaine 
exposure, ΔFosB accumulation in the NAc results in G9a repression and 
decreased global levels of H3K9me2, preventing G9a’s ability to maintain 
normal levels of gene expression and enhancing behavioural responses to the 
drug (Maze et al., 2010; Maze and Nestler, 2011). 
Histone phosphorylation is also an important component of the epigenetic 
responses to drugs of abuse. Brami-Cherrier and colleagues (2009) reported that 
cocaine induces a robust phosphorylation of histone H3 within the NAc at the c-
fos and c-Jun promoters (Brami-Cherrier et al., 2009). Histone H3 
phosphorylation is positively regulated by the MAPK/extracellular-signal 
regulated kinase (ERK) cascade, which includes steps to phosphorylate ERK 
and MSK-1-induced phosphorylation of histone H3 (Brami-Cherrier et al., 
2005; Bertran-Gonzalez et al., 2008). Nuclear accumulation of dopamine and 
cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) acts to inhibit PP1, 
thereby preventing histone dephosphorylation (Stipanovich et al., 2008). 
Critically, these pathways control behavioural responses to cocaine by 
inhibiting dopamine D1 receptors, ERK, DARPP-32 and MSK-1, all of which 
diminish drug-induced locomotor responses or drug CPP (Stipanovich et al., 
2008; Brami-Cherrier et al., 2009). Thus, these data confirm that changes in 
histone modifications may influence the transcription of genes involved in 
mediating cocaine-induced behaviour.  
 
2.5.2. DNA methylation and drug addiction 
Although the majority of studies have focused on histone modifications, DNA 
methylation is also a critical component of the epigenetic response to drug-
related behaviours. Several recent studies have provided crucial evidence of the 
role of DNA methylation in cocaine-induced neuronal plasticity in the NAc and 
hippocampus (Im et al., 2010; LaPlant et al., 2010, Paper I). Reports have 
demonstrated that acute cocaine treatment induces rapid changes in the 
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expression of Dnmt3a and Dnmt3b genes in the NAc, suggesting dynamic 
control of DNA methylation by drugs of abuse. Cocaine treatment also resulted 
in increased methylation of protein phosphatase-1 catalytic subunit (PP1c) 
promoter region, and binding of MeCP2 at the promoter. These changes were 
associated with transcriptional downregulation of PP1c in the NAc. In contrast, 
acute and repeated cocaine administrations induced hypomethylation and 
decreased binding of MeCP2 at the fosB promoter, which was associated with 
transcriptional upregulation of fosB in the NAc (Paper I). Im and colleagues 
(2010) investigated a possible role for MeCP2 in the dorsal striatum in the 
escalating cocaine intake observed in rats with extended access to the drug and 
found that MeCP2 knockdown prevented escalation of cocaine self-
administration during extended access (Im et al., 2010). It has been shown that 
NAc-specific manipulations that block DNA methylation potentiated cocaine 
reward and NAc-specific Dnmt3a upregulation attenuated cocaine reward 
(LaPlant et al., 2010). Recent reports indicate that epigenetic changes in brain 
regions outside of the striatum are also important regulators of drug memories. 
It has been found that DNA methylation within the hippocampus and prelimbic 
cortex is necessary for the establishment and maintenance of cocaine-induced 
CPP (Han et al., 2010; Day and Sweatt, 2011).  
 
2.5.3. microRNA and drug-related behaviour 
Several recent studies have demonstrated that microRNAs are important in 
addiction-related behaviours. For example, Hollander and colleagues (2010) 
found that cocaine self-administration upregulated microRNA miR-212 
expression in the rat striatum and also that enhanced miR-212 levels in this 
brain region decreased cocaine reward (Hollander et al., 2010). It appears that 
the actions of miR-212 depend upon upregulation of CREB, which is known to 
decrease the rewarding effects of cocaine (Robinson and Nestler, 2011). Im et 
al. (2010) demonstrated that MeCP2 may interact homeostatically with miR-
212 to control Bdnf expression and cocaine intake. Therefore, it has been 
suggested that the CREB-miR212-MeCP2-Bdnf mechanism is partly respon-
sible for tolerance to cocaine and the escalation in its intake (Robinson and 
Nestler, 2011). Moreover, recent studies have demonstrated that overexpression 
of miR-124 in the NAc of rats reduces cocaine place conditioning, whereas 
overexpression of miR-181 causes the opposite effect. These data indicate that 
microRNAs may play an essential role in drug tolerance and escalation of 
intake (Chandrasekar and Dreyer, 2009; Robinson and Nestler, 2011).  
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3. The role of early-life stress  
as a predictor of drug addiction 
Data from various clinical and preclinical studies have shown that stressful 
experiences in early life represent one of the major risk factors for the 
development of a wide range psychopathologies including drug addiction. 
Early-life stress can result in permanent hypothalamic-pituitary-adrenal (HPA) 
axis changes, morphological changes in the brain and gene expression changes 
in the mesolimbic dopamine reward pathway, which are implicated in the 
development of drug addiction (for a review see Enoch, 2011).  
Stress, which refers to processes involving perception, appraisal and 
response to harmful, threatening or challenging events or stimuli (Levine, 2005; 
Sinha, 2008), activates the HPA axis (Figure 5). The magnitude of the HPA 
response to stress is a function of the neural stimulation of hypothalamic 
corticotrophin-releasing factor (CRF) release, which stimulates the release of 
adrenocorticotrophic hormone (ACTH) from the pituitary gland (Smith and Vale, 
2006). In turn, ACTH induces the adrenal glands to release glucocorticoids 
(GCs) (such as cortisol in humans and corticosterone in rodents). It is well 
established that GCs exert their effects via two ligand-dependent transcription 
factors: the glucocorticoid receptor (GR) and the mineralocorticoid receptor 
(MR), which, in turn, regulate patterns of downstream gene expression during 
development and in adulthood (McEwen and Sapolsky, 1995; Seckl and 
Meaney, 2004; Akil, 2005; De Kloet et al., 2005). The rate of secretion of GCs 
is regulated by negative feedback that suppresses CRF and ACTH at the level of 
hypothalamus and pituitary (Sapolsky, 1996; De Kloet et al., 1998; McEwen, 
1998; Shea et al., 2004). The hippocampus is also important for GC negative 
feedback regulation of the HPA axis. The hippocampus contains a high 
concentration of both GR and MR receptors, and infusion of GCs into this 
structure reduces basal and stress induced GC release (Diorio et al., 1993; 
McEwen, 2000; Smith and Vale, 2006) 
The activation of the HPA axis in response to acute stress is essential for 
survival, whereas chronic activation results in increased risk for several physio-
logical problems, such as anxiety, depression and addiction to drugs (Sapolsky 
et al., 2000, Ambroggi et al., 2009; Enoch, 2011).  
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Figure 5. Schematic diagram of the hypothalamic-pituitary-adrenal (HPA) axis. 
Adrenocorticotrophic hormone (ACTH); corticotrophin-releasing factor (CRF; modified 
from Shea et al., 2004).  
 
Several preclinical studies have demonstrated that early-life stress leads to 
heightened responsiveness to stress and alterations to the HPA system 
throughout the lifespan (Plotsky and Meaney, 1993; Heim and Nemeroff, 2001; 
Pryce et al., 2005). Disturbances in mother-infant interaction have been 
demonstrated to be a natural stressor that may lead to maladaptive development 
(Daniels et al., 2004; Grace et al., 2009). Animal studies indicate that the 
quality of maternal care (arched back nursing, grooming, licking of pups) 
during the first two weeks of life influences the development of individual 
differences in behavioural and HPA responses to stress in offspring (Liu et al. 
1997; Caldji et al. 2000; Meaney and Szyf, 2005). For example, it has been 
found thar poor maternal contact in early life increases plasma ACTH and 
corticosterone responses to stress in adult rats, decreases hippocampal GR 
mRNA levels and reduces GC feedback sensitivity (Liu et al. 1997; Weaver et 
al., 2001 and 2004; Weaver, 2009; Enoch, 2011).  
Rodent models of early-life stress, such as maternal separation (MS) and 
neonatal isolation, have been used to investigate the relationship between early 
life stress and susceptibility to drug addiction. The majority of these studies 
suggest that early manipulations lead to increased drug-taking behaviour in 
adulthood; however, the exact mechanism of how MS causes these behavioural 
changes is not yet understood.  
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3.1. Maternal separation and drug addiction 
MS is an animal model that has been studied to characterize the long-term 
effects of early-life experience on subsequent behaviour in adulthood (Plotsky 
and Meaney, 1993; Pryce and Feldon, 2003; Daniels et al., 2009). The MS 
model involves the daily separation (15 min to 6 h) of litters from the dams 
during a critical period of development, typically from postnatal day (PND) 2 to 
14. These brief separations cause profound neurochemical and behavioural 
changes in the pups that remain in adulthood (Moffett et al., 2007). Rats that are 
separated for 15 min per day (MS15) during the first 2 weeks of life (short MS) 
show less stress reactivity than animals separated for 180 min per day (MS180, 
long separation). MS15 and MS180 animals have been used in many studies 
and are typically referred to as “handled” and “maternally separated” animals, 
respectively. Commonly used control groups are a group reared under standard 
animal facility conditions (AFR) and a non-handled (NH) group (Meaney et al., 
1988; Huot et al., 2002; Moffett et al., 2007).  
As models of early life stress, MS and neonatal isolation (a model where 
pups are separated daily from the dams and also from littermates) have been 
demonstrated to affect psychostimulant-induced behaviour (Moffett et al., 
2007). For example, it has been found that MS alters cocaine-induced 
locomotor activity in rats and mice (Brake et al., 2004; Kikusui et al., 2005) and 
behavioural sensitisation to cocaine (Li et al., 2003). Brake and colleagues 
(2004) have found that MS and NH rats displayed a dose-dependent greater 
sensitivity to cocaine-induced locomotor activity compared with a handled 
group (Brake et al., 2004). Studies by Marin and Planeta (2004) demonstrated 
that male adolescent rats exposed to MS exhibited an enhanced locomotor 
response to cocaine; however, this response was not observed in adult rats 
(Marin and Planeta, 2004). Kikusui and colleagues (2005) used mice in MS 
manipulation procedures and found that repeated MS increased the locomotor 
response to cocaine regardless of gender (Kikusui et al., 2005). It has also been 
found that handled rats (exposed to daily 15-min isolation periods as pups) 
showed an attenuated CPP for amphetamine compared with NH animals 
(Campbell and Spear, 1999). In addition, several previous studies demonstrated 
that a daily neonatal isolation of 1 h over PND 2–9 enhanced acquisition and 
maintenance of cocaine self-administration (Kosten et al., 2000, 2004 and 2005; 
Zhang et al., 2005; Moffett et al., 2007), and separated rat pups drank more 
alcohol and self-administered more cocaine compared with the control animals 
(Matthews et al., 1996; Kosten et al., 2000; Huot et al., 2001; Flagel et al., 
2003). Therefore, it is assumed that early life stress leads to profound and 
lasting changes in the responsiveness of mesocorticolimbic dopamine neurons 
to stress and psychostimulants (Brake et al., 2004; Enoch, 2011). Studies by 
Piazza and colleagues demonstrated that the potential for rats to self-administer 
drugs can be predicted by the response of mesolimbic dopaminergic neurons to 
stress, i.e., animals that were more sensitive to the dopamine-releasing actions 
of stress were more likely to display addictive behaviour (Piazza et al., 1991; 
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Piazza and LeMoal, 1996). Thus, it is highly likely that stress increases the 
activity of the dopaminergic brain systems that mediate drug-induced rewarding 
effects (Brady and Sonne, 1999).  
Moreover, a growing body of evidence demonstrates that MS results in 
increased HPA responsivity to stress, leading to increased adrenal GC release 
during stress, and in turn, GCs appear to regulate mesolimbic DA systems 
(Meaney et al., 2002). For example, it has been found that stress exposure and 
increased levels of GC enhance DA release in the NAc, and suppression of GC 
by adrenalectomy reduces extracellular levels of DA under basal conditions (for 
a review see Sinha, 2008). Several animal studies have shown that depletion of 
GC by adrenalectomy reduces drug and alcohol consumption (Fahlke et al., 
1994; Marinelli et al., 1997; Marinelli and Piazza, 2002). It has also been found 
that mice with GR gene deletions show a dose-dependent decrease in 
motivation to self-administer cocaine (Deroche-Gamonet et al. 2003; Sinha, 
2008). Therefore, the activation of the HPA axis and subsequent release of GC 
may also play an important role in the acquisition of addiction to 
psychostimulant administration (Piazza and LeMoal, 1996; Mantsch et al., 
1998; Goeders, 2002 and 2003; Meaney et al., 2002).  
 
 
3.2. Maternal separation and epigenetic modifications 
There is a growing body of evidence that demonstrates that early-life adversity 
results in a change in the epigenome. It has been found that epigenetic 
modifications, such as DNA methylation, alter gene expression programming in 
the brain that lasts into adulthood. Using rodent models, several studies have 
demonstrated that the adult offspring of mothers that exhibit increased levels of 
pup licking/grooming (referred to as high-LG mothers) during the first week of 
life show increased hippocampal GR expression, decreased CRF expression and 
more modest HPA stress responses compared with low-LG mothers (Liu et al., 
1997; Francis et al., 1999; Meaney and Szyf, 2005; Weaver et al., 2006; 
McGowan et al., 2008). Weaver and colleagues (2004) observed that poor 
maternal care in rats alters DNA methylation at a specific sequence motif 
upstream of the GR gene (Nr3c1) in the hippocampus of the offspring. They 
found significantly greater methylation of the exon 17 GR promoter sequence in 
the offspring of the low-LG mothers (Weaver et al., 2004). These data 
demonstrate that in low-LG offspring, higher methylation of the GR promoter 
suppresses GR expression; therefore, adult offspring of low-LG mothers have 
lower levels of GR (Liu et al., 1997; Champagne et al., 2003; Weaver et al., 
2004). A human postmortem hippocampal study showed that suicide victims 
exposed to childhood maltreatment had decreased GR (Nr3c1) mRNA levels 
and increased cytosine methylation in Nr3c1 promoter regions (McGowan et 
al., 2009; Enoch, 2011).  
The exact mechanism of how maternal behaviour alters epigenetic 
programming in the offspring brain is unclear. One hypothesis is that maternal 
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behaviour increases hippocampal serotonin (5-HT) turnover and activated 
5-HT7 receptors increase cAMP activity in the offspring. Increased cAMP 
activity results in activation of PKA and CREB, and the subsequent 
phosphorylated-CREB (pCREB) activity drives expression of the transcription 
factor NGFI-A (nerve growth factor-inducible protein A) (Figure 6). This 
transcription factor in turn recruits the histone acetyltransferase CBP and also 
MBD2 to the GR promoter (Weaver et al., 2004; Weaver, 2007). It is assumed 
that the increased histone acetylation triggered by CBP facilitates the 
demethylation of the gene by MBD2 and/or other DNA demethylases (Szyf, 
2009).  
   
 
However, recent studies have revealed that patterns of epigenetic modification 
programmed early in life may be reversible using epigenetic modulators. For 
example, it has been found that injecting the HDAC inhibitor trichostatin A 
(TSA) into the left lateral ventricle of adult offspring of low-LG mothers 
reversed the epigenetic programming of the GR exon 17 promoter and re-
established stress responsivity (Cervoni and Szyf, 2001; Cervoni et al., 2002; 
Weaver et al., 2004). Conversely, it has been found that injecting the amino acid 
methionine, which is the precursor of SAM, into the ventricle of adult offspring 
of high-LG mothers resulted in increased DNA methylation and downregulation 
of GR and heightened stress responsivity (Weaver et al., 2004 and 2005; Szyf, 
2011).  
Figure 6. Model of the epigenetic reprogramming of hippocampal glucocorticoid 
receptor gene expression and stress responses induced by maternal behaviour.  
(A)-acetylation; (P)-phosphorylation; (LG-ABN)-licking/grooming and arched-back 
nursing (modified from Bennett, 2011). 
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Early-life stress has been shown to bring about epigenetic changes of other 
genes. For example, it has been found that early-life stress in mice caused 
enduring hypersecretion of corticosterone and alterations in passive stress 
coping. This phenotype was accompanied by a persistent upregulation of 
arginine-vasopressin (Avp) expression and sustained DNA hypomethylation in 
the hypothalamic paraventricular nucleus (PVN) (Murgatroyd et al., 2009). The 
experiments by Roth and colleagues (2009) demonstrated that early 
maltreatment produces persistent changes in methylation of the Bdnf gene 
promoter and decreases Bdnf expression in the PFC of adult rats (Roth et al., 
2009). Subsequently, Franklin et al. (2010) found that chronic and unpredictable 
MS alters the profile of DNA methylation in the promoter of several genes, 
such as Mecp2, corticotrophin-releasing factor receptor 2 (Crhr2) and 
cannabinoid receptor-1 (Cnr1), in the germline of the separated males, and 
comparable changes in DNA methylation are present in the brain of the 
offspring and are associated with altered gene expression (Franklin et al., 2010). 
Together, these data suggest that alterations in epigenomic programming 
impact phenotype, which is expressed as behaviour and that early-life stress 
leaves its impact on the genome by systematic readjustment of DNA 
methylation patterns (Szyf, 2009). 
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AIMS OF THE STUDY 
The general aim of this study was to investigate the role of DNA methylation in 
the development of cocaine-induced behavioural sensitisation in mice and rats.  
 
The more specific aims for this thesis were: 
 
1. To determine: a) the role of cocaine treatment on the expression of DNMTs 
and selected genes in the NAc of mice; and b) to assess the effect of the 
DNMT inhibitor zebularine on cocaine-induced gene expression changes 
and the development of behavioural sensitisation in adult mice. 
 
2. To investigate the role of the methyl donor SAM on cocaine-induced gene 
expression changes and the development of behavioural sensitisation in adult 
mice. 
 
3. To evaluate whether the early-life stress alters the expression of DNMTs and 
selected genes in the NAc of infant and adult rats and whether these changes 
are associated with the development of cocaine-induced behavioural 
sensitisation in adulthood. 
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MATERIALS AND METHODS 
1. Animals and housing conditions (Papers I–III) 
All experiments were performed in accordance with EU guidelines (directive 
86/609/EEC) on the ethical use of animals using the experimental protocol 
approved by the Ethics committee of the University of Tartu Medical Faculty. 
Male C57BL/6 mice, 4–5 months old, weight 25–30g were obtained from 
Scanbur BK, Sweden (Papers I, II) and 20–25 pairs of male and female Wistar 
rats were obtained from Harlan Laboratories, Netherlands (Paper III). All 
animals were housed in standard polypropylene cages under temperature and 
humidity-controlled rooms with 12 h light-dark cycle (light from 7:00 a.m.) and 
were allowed access to rodent chow and water ad libitum. Animals were 
allowed to acclimate to laboratory conditions and were handled at least 4–7 
days before use in behavioural testing. All behavioural experiments were 
conducted during the light phase in an isolated experimental room.  
 
 
2. Maternal separation and handling procedures  
(Paper III) 
As the pups were born (total 46, from 3–5 litters), female offspring were 
removed and male offspring were randomly assigned to one of three groups. 
During the experiment, every dam had 8 pups. The experimental groups are as 
follows: (1) AFR where the dams and pups were handled only on PND10 for a 
cage change and were not separated; (2) handled group (MS15) where pups 
were handled and separated to a new cage on PND2-15 for 15 min and then 
returned to the home cage; (3) maternally-separated group (MS180) where pups 
were removed from the home cage on PND2-15 for 180 min and placed 
individually into a new cage. At the end of the separation pups were placed 
back into their home cage with the dam. The manipulation of pups in the MS15 
and MS180 groups was initiated at 10:00 a.m., and after the manipulation, we 
monitored dam and pup behaviour in the home cage for 10 min. We performed 
seven separation procedures to collect pups from different dams for behavioural 
and neurochemical tests. We considered AFR as a control group for both 
handling (MS15) and separation (MS180) groups. A comparison of MS15 and 
MS180 groups enables collection of “time course” data on MS. Cocaine-
induced locomotor activity was evaluated on PND120-140. Animals were 
allowed to acclimate to laboratory conditions and were handled at least seven 
days prior to behavioural experiments. All behavioural experiments were 
conducted during the light phase in an isolated experimental room. For the 
evaluation of neurochemical changes, rats were euthanised on PND15 and 
PND120. 
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3. Drug administration (Papers I–III) 
Cocaine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
sterile saline (0.9% NaCl) and administered intraperitoneally (i.p.) at a dose of 
15 mg/kg (Paper I) and 10 mg/kg (i.p.) (Papers II, III) immediately prior to 
locomotor activity training. Zebularine (Tocris Bioscience, UK) was dissolved 
in sterile saline and administered intracerebroventricularly (i.c.v.) 300 ng/0.5 l 
20 min before cocaine or saline (0.1 ml/10 g body weight, i.p.) treatment (Paper 
I). SAM (Sigma-Aldrich Co, St. Louis, MO, USA) was dissolved in sterile 
saline and administered (i.p.) at a dose of 4520 mg/kg, 10 mmol/kg 20 min 
before cocaine treatment (Paper II).  
 
 
3.1. Intracerebroventricular cannula implantation (Paper I) 
For i.c.v. injection cannula implantation, mice were anesthetized with Fentanyl/ 
fluanisone (trade name Hypnorm, VetaPharma, Leeds, UK) and midazolam 
(trade name Dormicum, Roche, Basel, Switzerland). During surgery, each 
mouse was implanted with a 26-gauge bilateral stainless steel guide cannula 
(Plastics One, Roanoke, USA) from which the injector extended 0.5 mm to end 
in the ventricle. Stereotaxic coordinates were follows: antero-posterior, –0.4 
mm from bregma, –1.25 mm lateral from the midline, and –2.0 mm from 
bregma measured from the tip of the cannula guide (Paxinos and Franklin, 
2001). Animals were habituated to dummy cannula removal and given 4 days of 
recovery and handling before the start of the experimental procedure. At the 
beginning of the study, target coordinates and proper cannula placement were 
verified by slowly injecting 1 μl of methylene blue dye into the cannulas of the 
first four mice, while they were under anesthesia. After waiting 5 min for the 
dye to circulate through the ventricles, the animals were sacrificed. Brains were 
removed, sliced at the point of cannula entry and target coordinates were 
verified. 
 
 
4. Behavioural experiments  
4.1. Locomotor activity measurement (Papers I–III) 
Horizontal locomotor activity was monitored in standard polypropylene cages 
(36 × 20 × 15 cm) that were illuminated uniformly with dim light. A light-
sensitive video camera, connected to a computer, was mounted about 1.5 m 
above the observation cage and locomotor activity of 8 animals at a time was 
monitored and analysed using VideoMot2 software (TSE Systems, Germany) 
(Papers I, II). In Paper I, mice (n=11) were randomly assigned to one of the 
following treatment groups: (1) Saline (“SAL”), mice were treated for 7 days 
with saline 0.1 ml/10 g body weight (i.p.); (2) Acute cocaine (“AC”), mice were 
treated for 6 days with saline and on the 7th day with cocaine hydrochloride; 
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(3) repeated cocaine (“RC”), mice were treated for 7 days with cocaine hydro-
chloride. On the 1st and 7th treatment days, locomotor activity was recorded for 
60 min after the last injection. On the 2nd through to the 6th treatment days, mice 
were injected and placed in the test cages for 60 min without locomotion 
recording. To investigate the effect of zebularine, i.c.v. infusions of zebularine 
(300 ng/0.5 l, injection speed 0.1 µl/min) or saline (0.5 l) were performed 
20 min before cocaine or saline (0.1 ml/10 g body weight, i.p.) treatment. Mice 
(n=7–12) were randomly assigned to one of the following treatment groups: 
(1) saline (i.c.v.) + saline (i.p.) “S+S”; (2) zebularine (i.c.v.) + saline (i.p.) 
“Z+S”; (3) saline (i.c.v.) + cocaine (i.p.) “S+C” and (4) zebularine (i.c.v.) + 
cocaine (i.p.) “Z+C”. Locomotor activity was recorded for 60 min after i.p. 
injection daily for 7 days.  
In Paper II, mice were treated for 7 days i.p. with sterile saline (0.1 mL/10 g 
body weight) or SAM (4520 mg/kg, 10 mmol/kg, i.p.) 20 min before cocaine 
hydrochloride administration (10 mg/kg, i.p.). Animals (n=17–22) were 
randomly assigned to one of the following treatment groups: (1) Saline + Saline 
“S+S”; (2) SAM + Saline “M+S”; (3) Saline + Cocaine “S+C” and (4) SAM + 
Cocaine “M+C”. Locomotor activity was recorded for 90 min after the second 
injection on days 1, 3, 5, and 7. On the days 14 and 28, all groups were tested 
for locomotor activity for 90 min after cocaine challenge (7 mg/kg, i.p., n=8). 
On the days 8–13 and 15–27 mice did not receive any treatment. Mice were 
sacrificed 24 h after the end of the repeated treatment. 
In Paper III, cocaine hydrochloride was administered i.p. at a dose of 
10 mg/kg immediately prior to locomotor activity training. Locomotor activity 
was monitored in the standard polypropylene cages (54 × 32 × 20 cm) of 4 
animals at a time and analysed. For experiments of acute cocaine treatment, 
adult male rats (PND120–140) from each of the AFR, MS15 and MS180 groups 
(n=13; weight 485–520g) were treated for 4 days with saline (2.5 ml/kg, i.p.) 
and on the 5th day with cocaine hydrochloride (10 mg/kg, i.p.). For experiments 
assessing the effect of repeated cocaine treatment, all rats received cocaine 
(10 mg/kg, i.p.) once daily for 5 consecutive days. On the 1st, 3rd and 5th 
treatment days, locomotor activity was recorded for 60 min after treatment. On 
the 2nd and 4th treatment days, rats were treated and placed in the test cages for 
60 min without recording locomotion. 
 
 
4.2. Exploration box test (Paper III) 
At PND120, adult males from AFR, MS15 and MS180 groups (n = 8 animals in 
each group) were tested for exploratory behaviour. The test apparatus (modified 
from Matto et al., 1996 and Mällo et al., 2007) was made of metal and 
comprised an open area of 50 (width) × 100 (length) × 40 (height) cm with a 
small compartment (20 × 20 × 20 cm) attached to one of the shorter sides of the 
open area. The open area was divided into eight squares of equal size 
(25 × 25 cm) and four objects were situated in specific positions. Three objects 
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were unfamiliar (a glass jar, a cardboard box, a wooden handle) and one was 
familiar (food pellet), and the objects remained the same throughout the 
experiment. The floor of the small compartment was covered with wood 
shavings and was directly linked to the open area via an opening (size 
20 cm × 20 cm). The rat was placed into the small compartment, which was 
then covered with a lid, and during the 15 min test session, the following 
measures were taken by the observer: (a) latency to enter the open area with all 
four paws; (b) entries into the open area; (c) line crossings; (d) rearings; (e) 
exploration of the three unfamiliar objects in the open area and (f) the time 
spent exploring the open area. The exploration test box was cleaned after each 
animal. To provide an index of exploration (considering both the elements of 
inquisitive and inspective exploration), the scores for line crossings, rearings 
and object investigations were summed for each animal. 
 
 
5. Tissue isolation (Papers I–III) 
Mice and rats were sacrificed by decapitation. The NAc, hippocampus, 
cerebellum and PFC were rapidly dissected out on chilled ice-cold plate and 
frozen immediately in liquid nitrogen and stored at –80 °C until RNA and DNA 
extracts and protein lysates were prepared. The NAc was dissected out using a 
round-shape puncher. 
 
 
6. PC12 cells and DNMT activity measurement (Paper II) 
Rat pheochromocytoma cells (PC12) purchased from German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) were 
cultured in a humidified 5% CO2/95% air atmosphere at 37 C. The PC12 cell 
line was maintained in RPMI 1640 medium (Gibco CO, USA) supplemented 
with 10% heat-inactivated horse serum and 5% fetal bovine serum (Gibco CO, 
USA). Cells were grown on polyethyleneimine (Sigma-Aldrich, St. Louis, MO, 
USA) coated plastic dishes (Nunc, Thermo Fisher Scientific, MA, USA) at a 
density of 106 cells/ml. The cells from the 4th to 7th passages were treated with 
0.5 mM SAM and used for the DNMT activity, gene expression, and DNA 
methylation experiments. For single SAM treatment, 0.5 mM SAM solution 
(prepared in RPMI medium) was added to growing cells at time points 0, 2, 6, 
12 and 24 h. For repeated SAM experiment, 0.5 mM SAM was added to the 
cells once a day for 7 days and nuclear extract was prepared 0, 2, 6, 12 and 24 h 
after last treatment. Control measurements were performed with vehicle (RPMI 
medium) treated cells. Nuclear extract was isolated from cells using EpiQuik 
Nuclear Extraction kit (Epigentek Group, Brooklyn, USA). Total DNMT 
activity was determined using an EpiQuik DNMT activity assay kit (Epigentek 
Group, Brooklyn, USA). DNMT activity (OD/mg/h) was calculated according 
to the formula:  
39 
 
 
Two dishes combined as a sample, 4 samples per group were used. Experiments 
were repeated twice. 
 
 
7. Gene expression analyses  
7.1. Measuring mRNA levels using qPCR (Papers I–III) 
Total RNA was extracted from mouse or rat NAc, hippocampus, cerebellum, 
PFC and from cells using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) 
according to the manufacturers’ protocol. cDNA was synthesised from 400 ng 
or 750 ng of total RNA using the First Strand cDNA Synthesis Kit (Fermentas 
Inc, Burlington, Canada). Quantitative PCR (qPCR) was performed using an 
ABI PRISM 7000 Sequence Detection System equipped with ABI Prism 7000 
SDS Software (Applied Biosystems Inc, USA). Primers for mouse or rat 
Dnmt1, Dnmt3a, Dnmt3b, A2AR, fosB, Reln were designed using Primer3 with 
BLAST sequence verification. Primers were synthesised by TAG Copenhagen 
AS (Copenhagen, Denmark) and were listed in table 1. Commercial assays were 
from SABiosciences (Qiagen, Hilden, Germany) for measuring mouse PP1c 
(Cat. No. PPM37272B), Cck (Cat. No. PPM24836G), Gal (Cat. No. 
PPM25148F), Slc17a7 (Cat. No. PPM35361A) and rat PP1c (Cat. No. 
PPR42515B) mRNA expression. PCR amplification was performed in a total 
reaction volume of 25 l in three parallels. The reaction mixture consisted of 
1 l First Strand cDNA diluted template, 12.5 l 2x Master SYBR Green qPCR 
Master Mix (Applied Biosystems Inc, USA), 10.5 l H20 and 1 l gene-specific 
10 M PCR primer pair stock. The PCR amplification was performed as 
follows: denaturation step at 95 °C for 10 min, followed by denaturation at 
95 °C for 15 s, and annealing and extension at 60 °C for 1 min, repeated for 
40 cycles. SYBR Green fluorescence was measured after each extension step 
and amplification specificity was confirmed by melting curve analyses and gel 
electrophoresis of the PCR products. Serial dilutions (fivefold) of total RNA 
from one control sample were analysed for each target gene and used to 
construct linear standard curves from which the concentrations of the test 
sample and efficiency of the PCR reaction were calculated. Results were 
normalised to -Actin or Gapdh (Glyceraldehyde-3-phosphate dehydrogenase) 
using the CT method (Livak and Schmittgen, 2001; Schmittgen and Livak, 
2008). 
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7.2. Gene expression profiling (Paper II) 
Total RNA was extracted from mouse NAc as described in the section 7.1. 
Tissues from two animals were combined to a sample, 4 samples per group 
used. RNA quantity and quality were assessed using the NanoDrop-1000 
spectrophotometer and the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, USA). Labeled cRNA was prepared using Illumina TotalPrep RNA 
amplification Kit according to the manufacturers’ instructions using 750 ng of 
total RNA as a template (Ambion Inc, Austin, TX, USA). The Illumina 
BeadChip platform (Illumina, San Diego, USA) and the corresponding whole-
genome Mouse Ref-8 v2.0 BeadChip (approximately 25,698 transcripts; over 
19,100 genes) were used for the gene expression analysis. The raw data was 
analysed with Illumina BeadStudio Gene Expression Module v3.3.7 (Illumina, 
San Diego, USA). Further data analysis was performed with R version 2.13.0 
(http://www.r-project.org)/Bioconductor software (www.bioconductor.com) 
using lumi (Du et al., 2008) and limma packages (Smyth, 2005). The 'fdr' 
method to adjust the p values for multiple testing was used to control the false 
discovery rate (Benjamini and Hochberg, 1995). With a statistical discrimi-
nation p value set at less than 0.05, limma software and B-statistics analyses 
were used to identify up- and downregulated genes and filtered for 1.5-fold or 
greater differences in expression in accordance with standards for microarray 
analysis (Allison et al., 2006). Gene ontology analysis was conducted using 
DAVID Bioinformatics Resources (Huang et al., 2009). 
Microarray data have been deposited in the Gene Expression Omnibus 
(GEO) repository (Edgar et al., 2002) and are accessible through GEO Series 
accession number GSE48365 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48365). 
 
 
8. DNA methylation assays 
8.1. Methylated DNA immunoprecipitation (Papers I–III) 
Methylated DNA immunoprecipitation (MeDIP) was performed using the 
EpiQuik Methylated DNA (Paper III) and Tissue Methylated DNA Immuno-
precipitation kit (Epigentek Group Inc, USA) according to the manufacturers’ 
protocol. Genomic DNA was extracted from mouse or rat (PND15 and 
PND120) NAc, cerebellum, PFC, sonicated into fragments ranging from 200–
1000 bp in size and divided into immunoprecipitated (IP) and input (IN) 
portions. IP DNA was incubated with anti-5-methylcytosine monoclonal 
antibody to bind methylated DNA. Normal mouse IgG from manufacturers of 
the EpiQuik MeDIP kit was used as a negative control. Methylated DNA 
(750 ng) was subjected to qPCR using commercial assays from SABiosciences 
(Qiagen, Hilden, Germany) for mouse Dnmt3a (Cat. No. EPMM102350-1A), 
Dnmt3b (Cat. No. EPMM106719-1A), PP1c (Cat. No. EPMM108835-1A), 
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fosB (Cat. No. EPMM109802-1A), Cck (Cat. No. EPMM111951-1A), Gal (Cat. 
No. EPMM105518-1A), Slc17a7 (Cat. No. EPMM110039-1A) (Papers I, II) 
and for rat Dnmt3a (Cat. No. EPRN107117-1A), PP1c (Cat. No. EPRN102434-
1A), A2AR (Cat. No. EPMM100909-1A) and Reln (Cat. No. EPRN105980-1A) 
(Paper III). To evaluate the relative enrichment of target sequences after 
MeDIP, the ratios of the signals in the IP DNA vs. IN DNA was calculated. The 
resulting values were standardised against the unmethylated control sequence 
Gapdh and fold changes were calculated. 
 
 
8.2. Methylation-specific qPCR analysis (Papers I, III) 
DNA was isolated from mouse and rat NAc using QIAmp DNA Mini Kit 
(QIAGEN, Hilden, Germany) and processed for bisulphite modification using 
Epitect Bisulfite Kit (QIAGEN, Hilden, Germany). qPCR was used to 
determine the DNA methylation status of mouse and rat PP1c gene. 
Methylation-specific qPCR primers were designed using Methprimer software 
(www.urogene.org/methprimer). Methylation-specific and unmethylated PCR 
primers were designed to target putative CpG islands detected in silico in the 
promoter or non-promoter regions of the PP1c gene and were synthesised by 
TAG Copenhagen AS (Copenhagen, Denmark). Primer sequences are listed in 
table 1. PCR reactions were performed as described in the section 7.1. The 
comparative Ct method was used to calculate differences in methylation 
between samples (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). 
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8.3. Primer sequences (Papers I–III) 
Table 1. The sequences of all primers (from TAG Copenhagen AS) used in this study.  
Target gene Primer sequences Species 
 mRNA qPCR primers  
Dnmt1 Forward: CCCATGCATAGGTTCACTTCCTTC Mouse 
Dnmt1 Reverse: TGGCTTCGTCGTAACTCTCTACCT Mouse 
Dnmt3a Forward: GCCGAATTGTGTCTTGGTGGATGACA Mouse 
Dnmt3a Reverse: CCTGGTGGAATGCACTGCAGAAGGA Mouse 
Dnmt3b Forward: TTCAGTGACCAGTCCTCAGACACGAA Mouse 
Dnmt3b Reverse: TCAGAAGGCTGGAGACCTCCCTCTT Mouse 
fosB Forward: ACAGATCGACTTCAGGCGGA Mouse 
fosB Reverse: GTTTGTGGGCCACCAGGAC Mouse 
A2AR Forward: AACCTGCAGAACGTCAC Mouse 
A2AR Reverse: GTCACCAAGCCATTGTACCG Mouse 
Gapdh Forward: GTCATATTTCTCGTGGTTCACACC Mouse 
Gapdh Reverse: CTGAGTATGTCGTGGAGTCTACTGG Mouse 
β-Actin Forward: ATGGTGGGAATGGGTCAGAAG Mouse 
β-Actin Reverse: TCTCCATGTCGTCCCAGTTG Mouse 
Dnmt1 Forward: AACGGAACACTCTCTCTCACTCA Rat 
Dnmt1 Reverse: TCACTGTCCGACTTGCTCCTC Rat 
Dnmt3a Forward: CAGCGTCACACAGAAGCATATCC Rat 
Dnmt3a Reverse: GGTCCTCACTTTGCTGAACTTGG Rat 
Dnmt3b Forward: GAATTTGAGCAGCCCAGGTTG Rat 
Dnmt3b Reverse: TGAAGAAGAGCCTTCCTGTGCC Rat 
A2AR Forward: AGTCAGAAAGACGGGAAC Rat 
A2AR Reverse: 
Reln Forward: 
Reln Reverse: 
CAGTAACACGAACGCAA 
CTGCTGGACTTCTCTACGGAT 
CAGTAGAGGTGGAAGGATGGG 
Rat 
Rat 
Rat 
Gapdh Forward: TGCCATCACTGCCACTCAGA Rat 
Gapdh Reverse: GTCAGATCCACAACGGATACATTG Rat 
β-Actin Forward: GTAACCCGTTGAACCCCATT Rat 
β-Actin Reverse: CCATCCAATCGGTAGTAGCG Rat 
 Methylation-specific qPCR primers  
PP1c methylated Forward: TTTTATGGGTTCGTAAAGAAGTTTC Mouse 
PP1c methylated Reverse: ACGAAAAAAACAAAATAACCGC Mouse 
PP1c unmethylated Forward: TTTATGGGTTTGTAAAGAAGTTTTG Mouse 
PP1c unmethylated Reverse: ACCACAAAAAAAACAAAATAACCAC Mouse 
PP1c methylated Forward: TTTTATGGGTTTGTAAAGAAGTTTC Rat 
PP1c methylated Reverse: CACGAAAAAAACAAAATAACCG Rat 
PP1c unmethylated Forward: TTTATGGGTTTGTAAAGAAGTTTTG Rat 
PP1c unmethylated Reverse: ACCACAAAAAAAACAAAATAACCAC Rat 
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9. Global DNA methylation analysis (Paper III) 
Total DNA was isolated from rat NAc and PFC using the QIAmp DNA Mini 
Kit (QIAGEN, Hilden, Germany). Global DNA methylation analysis was per-
formed using a MethylFlash Methylated DNA Quantification kit (Epigentek 
Group Inc., Farmingdale, NY, USA) according to the manufacturers’ instruc-
tions. Briefly, sample DNA (100 ng) was bound to high-DNA-affinity strip 
wells. The methylated fraction of DNA was detected using capture and 
detection antibodies and then quantified colorimetrically by reading the 
absorbance at 450 nm using a Tecan Sunrise microplate reader (Tecan Group 
Ltd., Switzerland). The amount of methylated DNA is proportional to the 
measured OD intensity. The percentage of methylated DNA (5-mC) in total 
DNA was quantified according to the manufacturers’ protocol and formula.  
 
 
10. Chromatin immunoprecipitation assay (Paper I) 
Chromatin immunoprecipitation (ChIP) of genomic DNA associated with 
MeCP2 was carried out according to the manufacturer protocol (Millipore Inc, 
USA). Mouse NAc was minced to small pieces and cross-linked in 1% for-
maldehyde (10 l/mg) for 15 min at 37 C. The minced, fixed tissue was homo-
genized in SDS lysis buffer, sonicated to produce 200–1000 bp genomic 
fragments, centrifuged for 15 min at 13,000 x g and the supernatant was used 
for ChIP assay. Immunoprecipitations were carried out at 4 C overnight with 
5 g of rabbit polyclonal MeCP2 antibody (AbCam, Cambridge, UK), negative 
control was anti-Rat IgG (Vector Laboratories Inc, Burlingname, USA) and 
positive control was anti-RNA Polymerase II from manufacturers ChIP kit. A 
portion of the sonicated DNA was left untreated to serve as input control. 
Immune complexes were collected with protein A beads and, according to the 
manufacturers’ protocol, sequentially washed two times with low salt buffer, 
high salt buffer, LiCl immune complex buffer and TE (Tris-EDTA) buffer. 
Immunoprecipitated DNA was subjected to qPCR using ChIP commercial 
assays from SABiosciences for mouse PP1c (Cat. No. GPM1037458(–)01A) 
and fosB (Cat. No. GPM1052791(–)01A).  
 
 
11. Western blotting (Papers I, III) 
The NAc was lysed in 10 vol (w/vol) of RIP-A lyses buffer: 50 mM Tris–HCl 
(pH 7.4), 150 mM NaCl, 1% Triton X 100 and protease inhibitors, homo-
genized, incubated 1 h at 4 °C and centrifuged 13,000 x g for 10 min at 4 °C 
(Papers I, III). The supernatants were resolved by electrophoresis on 8% SDS-
polyacrylamide gel. Proteins were transferred onto Hybond-P PVDF Transfer 
Membranes (Amersham Biosciences, UK) in 0.1 M Tris-base, 0.192 M glycine 
and 20% (w/w) methanol using an electrophoretic transfer system. The 
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membranes were blocked with 0.1% (w/w) Tween 20/TBS (T-TBS) containing 
5% (w/w) non-fat dried milk at room temperature for 1 h. After blocking the 
membranes were incubated overnight with one of the following antibodies: the 
anti-PP11 polyclonal antibody (1:1000, Millipore, Temecula, CA, USA) 
followed by incubation with biotinylated anti-rabbit IgM secondary antibody 
(1:1000) for 2 h and ABC solution for 30 min (Paper I); chicken anti-Dnmt3a 
(1:1000; ab14291; AbCam, USA) followed by incubation with secondary 
antibody anti-chicken HRP conjugate (1:2000; Pierce, USA) (Paper III). The 
membranes were incubated with ECL detection reagent (ECL, Amersham, UK) 
for 5 min to visualise proteins, and then exposed to autoradiography X-ray film 
(Amersham hyperfilm ECL, UK). To normalise immunoreactivity of the 
proteins, β-actin was measured on the same blot using a mouse monoclonal 
anti-β-actin antibody (1:10000; Sigma, St. Louis, USA) followed by incubating 
with an anti-mouse HRP-conjugated secondary antibody (1:2000; Pierce, US). 
The ratio of proteins of interest to β-actin were calculated and expressed as the 
mean OD ratio in arbitrary units ± SEM. 
 
12. Statistical analysis (Papers I–III) 
Behavioural data of all experiments were analysed using one-way or two-way 
ANOVAs for repeated measures and followed with Bonferroni’s post-hoc tests. 
Expression levels of genes and proteins, MeDIP and global DNA methylation 
and ChIP data were analysed using one-way or two-way ANOVAs or t-tests. 
Differences in methylation-specific qPCR and DNMT activity data were 
analysed using two-way ANOVAs with Bonferroni’s post-hoc tests. GraphPad 
Prism software (GraphPad, San Diego, CA, USA) was used for statistical 
analyses, and all data are expressed as the mean ± SEM. Significance levels 
were set to p<0.05.  
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RESULTS 
1. The effect of DNA methylation on cocaine-induced 
behavioural sensitisation in mice (Paper I) 
1.1. Acute and repeated cocaine treatment increases  
locomotor activity in mice 
The effects of acute (AC) and repeated cocaine (RC) treatment were assessed in 
adult mice. Our data showed that AC treatment significantly increased the 
locomotor activity of mice (Figure 7; two-way ANOVA repeated measures, 
treatment F2,35=18.9, p<0.0001; days effect F1,35=28.81, p<0.0001; interaction 
F2,35=7.43, p=0.002). We also found that after a daily injection of cocaine for 7 
days (RC), all mice displayed significantly enhanced locomotion in response to 
the same dose of cocaine on day 7 compared with day 1 (p<0.001), indicating 
behavioural sensitisation.  
 
Figure 7. Cocaine-induced behavioural sensitisation in mice. Mice were treated daily 
for 7 days, and ambulation was recorded for 1 h immediately after treatment. Treatment 
groups: saline (SAL), mice were treated with saline; acute cocaine (AC), mice were 
treated with saline for 6 days and with cocaine on the 7th day; repeated cocaine (RC), 
mice were treated daily for 7 days with cocaine. Two-way ANOVA, Bonferroni post-
hoc test, **p<0.01 AC treatment 1st vs. 7th day, ***p<0.001 RC treatment 1st vs. 7th day, 
n=11. Error bars indicate SEM. 
 
 
1.2. The effect of cocaine treatment on DNMT expression  
in the NAc and hippocampus 
Earlier studies by Miller and Sweatt (2007) demonstrated that mRNA levels of 
Dnmt3a and Dnmt3b were upregulated in the adult rat hippocampus following 
contextual fear conditioning. In our study, using qPCR, we found that AC 
administration caused an increase in Dnmt3a mRNA levels at both time points 
(1.5 h and 24 h), and Dnmt3b mRNA levels were increased at 24 h after AC 
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treatment compared with saline control (Figure 8A-C). However, the RC 
treatment did not change Dnmt3a and Dnmt3b mRNA levels significantly 
compared with saline control. There were also no significant changes in Dnmt1 
mRNA levels after AC and RC treatment. 
 
 
 
Figure 8. Acute (AC) and repeated (RC) cocaine treatment effects on (A) Dnmt1, (B) 
Dnmt3a and (C) Dnmt3b mRNA levels in the NAc at 1.5 and 24 h after treatment. One-
way ANOVA, Bonferroni post-hoc test, *p<0.05, **p<0.01, ***p<0.001 compared with 
respective saline (SAL) group, n=11. Error bars indicate SEM. 
 
We also assessed AC and RC treatment effects on Dnmts mRNA levels in the 
hippocampus. Our data showed that AC and RC treatment increased Dnmt3a 
mRNA levels at 1.5 h after treatment and Dnmt3b mRNA was enhanced only 
after AC treatment (Figure 9A-C). There were no changes in Dnmt3a and 
Dnmt3b mRNA levels at 24 h after cocaine treatment, and neither AC nor RC 
treatment altered Dnmt1 mRNA levels in the hippocampus of adult mice. 
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Figure 9. Acute cocaine (AC) treatment was associated with an upregulation of Dnmt3a 
and Dnmt3b mRNA levels in the hippocampus. (A–C) Cocaine effects on Dnmt1, 
Dnmt3a and Dnmt3b mRNA levels in the hippocampus at 1.5 h and 24 h after 
treatment. One-way ANOVA, Bonferroni post-hoc test, ***p<0.001 compared with 
respective saline (SAL) group, n=8. Error bars indicate SEM. 
 
 
1.3. Cocaine treatment alters the expression  
of selected genes in the NAc 
Upregulation of Dnmt3a and Dnmt3b may cause hypermethylation of certain 
gene promoters and consequently downregulate the expression of these genes. 
Therefore, a search for genes that show reduced expression following cocaine 
treatment was conducted. Several genes were tested, such as Bdnf, PP1c, fosB, 
and adenosine A2A receptor (A2AR), that participate in cocaine-induced 
neuroadaptations in the NAc and in silico analysis revealed that CpG islands 
were located within their promoter regions. Our qPCR data showed that PP1c 
mRNA levels were not altered at 1.5 h after AC and RC treatments (Figure 
10A). However, at 24 h after AC and RC treatment, PP1c mRNA levels were 
significantly decreased compared with saline control. To further confirm  
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PP1c mRNA downregulation in the NAc, Western blotting was performed. We 
found that PP1C protein levels were also decreased significantly at 24 h after 
AC and RC treatments compared with saline control (Figure 10B).  
As expected, it was found that AC and RC treatment resulted in upregulation 
of fosB mRNA levels at 1.5 h after treatment (Figure 10C) but there were no 
significant changes at 24 h after treatment. We also found that both AC and RC 
treatment decreased A2AR mRNA levels at 1.5 h after treatment (Figure 10D). 
However, we could not find significant changes in Bdnf mRNA levels (data not 
shown). As our aim was to investigate cocaine-induced long-lasting effects, 
PP1c and fosB genes were selected for additional DNA methylation studies. 
 
 
Figure 10. Altered patterns of expression of PP1c, fosB, and A2AR genes in the NAc 
after cocaine treatment. (A) The effects of acute (AC) and repeated cocaine (RC) 
administration on PP1c mRNA levels at 1.5 and 24 h after treatment. (B) AC and RC 
treatment resulted in a decrease in PP1C protein levels in the NAc at 24 h after 
treatment. (C) The effects of AC and RC administration on fosB and (D) on A2AR 
mRNA levels. One-way ANOVA, Bonferroni post-hoc test, *p<0.05, #p<0.001 
compared with respective saline (SAL) group, n=11. Error bars indicate SEM. OD, 
optical density. 
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1.4. Cocaine treatment alters DNA methylation  
in the PP1c and fosB promoters 
To determine the role of DNA methylation on cocaine-induced behavioural 
sensitisation, cocaine-induced changes in DNA methylation patterns within the 
PP1c promoter region was evaluated. Using a MeDIP assay, we found that both 
AC and RC treatment resulted in PP1c promoter-associated CpG island 
hypermethylation at 24 h after treatment (Figure 11B). Methylation-specific 
qPCR (MSP qPCR) data confirmed DNA hypermethylation within the PP1c 
promoter region at 24 h after AC and RC treatments (Figures 11A,C; two-way 
ANOVA, treatment F2,66=2.77, p=0.0699; methylation effect F1,66=31.24, 
p<0.0001; interaction F2,66=8.34, p=0.0006).  
                                 
 
 
Figure 11. Cocaine treatment was associated with altered DNA methylation in the PP1c 
promoters in the NAc at 24 h after treatment. (A) The position of the PP1c promoter-
associated CpG island. The target region indicates the locations of methylation-specific 
qPCR (MSP qPCR) primer pairs. (B) Using a methylated DNA immunoprecipitation 
(MeDIP) assay, we found that acute (AC) and repeated cocaine (RC) treatment elicited 
DNA hypermethylation associated with the PP1c promoter region. One-way ANOVA, 
Bonferroni post-hoc test, ***p<0.001 compared with saline (SAL) group, n=6. (C) 
Using MSP qPCR, we found that AC and RC treatment elicited hypermethylation 
associated with the PP1c promoter region. Two-way ANOVA, Bonferroni post-hoc test, 
*p<0.05, ***p<0.001 compared with methylated SAL group, n=11. Error bars indicate 
SEM. M, methylated; MeDNA, methylated DNA; U, unmethylated. 
A 
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Consistent with the upregulated fosB mRNA levels, our MeDIP data 
demonstrated hypomethylation at the fosB promoter at 1.5 h after AC and RC 
treatments (Figures 12A,B).  
 
   
Figure 12. Cocaine treatment was associated with altered DNA methylation in fosB 
promoters in the NAc at 1.5 h after treatment. (A) The position of the fosB promoter-
associated CpG island. The target region indicates the locations of the qPCR primer 
pairs. (B) Acute (AC) and repeated cocaine (RC) treatments elicited DNA hypo-
methylation associated with the fosB promoter region, determined using a methylated 
DNA immunoprecipitation (MeDIP) assay. One-way ANOVA, Bonferroni post-hoc 
test, ***p<0.001 compared with saline (SAL) group, n=6. Error bars indicate SEM. 
MeDNA, methylated DNA 
 
To further confirm that AC and RC administration altered DNA methylation at 
the promoter regions of the PP1c and fosB genes, a ChIP assay was performed. 
Consistent with the MeDIP and MSP qPCR results, ChIP analysis demonstrated 
that AC and RC cocaine treatments increased the PP1c promoter-associated 
MeCP2 binding by 1.8- to 2-fold in the NAc at 24 h after treatments (Figure 
13A). However, in the fosB promoter, AC and RC treatments were associated 
with a significant decrease in MeCP2 binding compared with saline control at 
1.5 h after treatment (Figure 13B).  
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Figure 13. Altered patterns of MeCP2 binding at the PP1c and fosB promoters in the 
NAc, determined using a chromatin immunoprecipitation (ChIP) assay. (A) Acute (AC) 
and repeated cocaine (RC) treatments increased MeCP2 binding at the PP1c promoter 
at 24 h after treatment and (B) decreased MeCP2 binding at the fosB promoter region at 
1.5 h after treatment. One-way ANOVA, Bonferroni post-hoc test, **p<0.01, 
***p<0.001 relative to SAL group, n=6. Error bars indicate SEM. 
 
 
1.5. The effect of the DNMT inhibitor zebularine  
on cocaine-induced DNA methylation and the development  
of behavioural sensitisation in mice 
As we found that cocaine treatment increased Dnmt3a and Dnmt3b mRNA 
levels and caused PP1c promoter-region hypermethylation, the effect of the 
DNMT inhibitor zebularine was assessed on cocaine-induced molecular 
changes and the development of behavioural sensitisation. To correlate the 
molecular changes with cocaine-induced behavioural sensitisation, a dose of 
zebularine (300 ng per 0.5 µl, i.c.v.) that did not affect basal locomotor activity 
and that decreased DNA methylation at the PP1c promoter region at 1.5 h after 
acute treatment (Figure 14A) was selected from a pilot study. 
For the co-treatment experiment, all mice received an i.c.v. infusion of saline 
or zebularine followed by i.p. injection of saline or cocaine (15 mg/kg) 20 min 
later. Locomotor activity was recorded for 60 min immediately after the last i.p. 
injection. Mice treated with repeated saline and cocaine (S+C) for 7 days 
displayed significantly enhanced locomotion on day 7 compared with day 1 
(Figure 14B; two-way ANOVA with repeated measures, treatment F3,39=15.98, 
p<0.0001; days effect F1,39=10.26, p=0.0027; interaction F3,39=5.69, p=0.0025). 
However, mice co-treated with zebularine and cocaine (Z+C) did not show any 
sensitisation on day 7 compared with day 1 (p<0.05). There was also no 
behavioural sensitisation after repeated zebularine and saline (Z+S) treatments. 
Thus, our results suggest that the inhibition of DNMTs by zebularine did not 
affect acute cocaine-induced locomotor activity but instead delayed cocaine-
induced behavioural sensitisation in mice.  
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Figure 14. Inhibition of DNMT by zebularine prevented cocaine-induced behavioural 
sensitisation. (A) Acute zebularine (ZEB) treatment elicited DNA hypomethylation 
associated with the PP1c promoter region in the NAc at 1.5 h after treatment, 
determined using a methylated DNA immunoprecipitation (MeDIP) assay. T-test, 
*p=0.034, n=4. (B) Mice were treated with cocaine (15.0 mg/kg, i.p.) alone or co-
treated with zebularine (300 ng per 0.5 µl, i.c.v.) daily for 7 days, and their ambulation 
was recorded for 1 h immediately after treatment. Mice were treated with saline (0.5 µl, 
i.c.v.) + saline (0.1 ml per 10 g body weight, i.p.; S+S); zebularine i.c.v. + saline i.p. 
(Z+S); saline i.c.v.+ cocaine i.p. (S+C); or zebularine i.c.v. + cocaine i.p. (Z+C). Two-
way ANOVA with repeated measures, Bonferroni post-hoc test, ***p<0.001 S+C 1st vs. 
7th day, n=7–12. Error bars indicate SEM. MeDNA, methylated DNA. 
 
Finally, we searched for molecular evidence to confirm that zebularine 
infusions i.c.v. prior to cocaine treatment altered DNA methylation levels at the 
PP1c promoter region in the NAc. Using a MeDIP assay, we found that 
repeated cocaine treatment (S+C) induced DNA hypermethylation at the PP1c 
promoter region at 24 h after treatment compared with the saline control group 
(S+S), and repeated zebularine and cocaine (Z+C) co-treatment prevented this 
effect (Figure 15A; one-way ANOVA, p<0.001 S+S vs. S+C, p<0.001 S+C vs. 
Z+C, n=6). Similarly, MSP qPCR data demonstrated that there was a significant 
decrease in DNA methylation associated with the PP1c promoter region in the 
Z+C group compared with the S+C group (Figure 15B; two-way ANOVA, 
treatment F3,45=39.0, p<0.0001, methylation effect F1,45=42.8, p<0.0001; 
interaction F3,45=80.8, p<0.0001). There were also significant changes between 
the zebularine- (Z+S) and the saline- (S+S) treated groups (p<0.05). 
Consistent with the PP1c promoter-associated CpG-island methylation 
results, we observed that zebularine attenuated cocaine-induced downregulation 
of PP1c mRNA levels (Figure 15C; one-way ANOVA, p<0.001 S+S vs. S+C, 
p<0.05 S+C vs. Z+C, n=6). These data indicate that the inhibition of DNMTs 
by zebularine reverses cocaine-induced PP1c gene hypermethylation and 
mRNA downregulation in the NAc. 
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Figure 15. The DNMT inhibitor zebularine altered DNA methylation at the PP1c 
promoter region in the NAc at 24 h after treatment. Mice were treated with saline (0.5 
µl, i.c.v.) + saline (0.1 ml per 10 g body weight, i.p.; S+S); zebularine i.c.v. + saline i.p. 
(Z+S); saline i.c.v. + cocaine i.p. (S+C); or zebularine i.c.v. + cocaine i.p. (Z+C). 
(A) Repeated Z+C co-treatment decreased DNA methylation levels associated with the 
PP1c promoter relative to the S+C group. (B) Repeated Z+C treatment decreased DNA 
methylation levels associated with the PP1c promoter relative to the S+C group. Two-
way ANOVA, Bonferroni post-hoc test, ***p<0.001 methylated S+C vs. methylated 
Z+C, n=5–7. (C) The blockade of PP1c methylation by zebularine was associated with 
enhanced PP1c mRNA levels. One-way ANOVA, Bonferroni post-hoc test *p<0.05 
S+C vs. Z+C, n=5–7. Error bars indicate SEM. M, methylated; MeDNA, methylated 
DNA; U, unmethylated. 
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2. The effect of treatment with SAM  
on cocaine-induced DNA methylation and  
behavioural sensitisation in mice (Paper II) 
2.1. SAM pretreatment potentiates the development and  
expression of cocaine-induced behavioural sensitisation in mice 
The effect of SAM (4520 mg/kg/day) on the behavioural sensitisation to 
cocaine (10 mg/kg/day) in adult mice was evaluated. Our data showed that 
repeated cocaine treatment (S+C) and repeated SAM and cocaine co-treatment 
(M+C) for 7 days caused significantly enhanced locomotion on day 7 compared 
with day 1 (Figure 16A) indicating the development of behavioural sensi-
tisation. There were also significant differences (p<0.001) between S+C and 
M+C groups on day 7. However, we did not find any difference in locomotor 
activity between SAM (M+S) and saline control (S+S) groups. 
In a cocaine (7 mg/kg i.p.) challenge study (on days 14 and 28), S+C and  
M+C groups demonstrated a robust sensitisation and exhibited more locomotor 
activity than the S+S group (Figure 16B). Importantly, the M+C group showed 
greater sensitisation compared with the S+C group. Cocaine challenge also 
increased locomotor activity in the M+S group compared with the S+S group 
but these changes were not substantial. These data demonstrated that exogenous 
SAM pretreatment did not affect the acute cocaine-induced locomotor response 
but instead potentiated the development and the expression of cocaine-induced 
behavioural sensitisation in mice.  
 
Figure 16. (A) The effect of treatment with S-adenosylmethionine (SAM) on cocaine-
induced behavioural sensitisation in mice. Two-way ANOVA repeated measurements, 
treatment F3,198=103.47, p<0.0001; days effect F3,198=47.07, p<0.0001; interaction 
F9,198=21.86, p<0.0001; Bonferroni post-hoc test, *p<0.05, saline + saline (S+S) vs. S + 
cocaine (S+C); #p<0.05, S+S vs. S-adenosylmethionine + cocaine (M+C); ^p<0.05, 
Saline + S-adenosylmethionine (M+S) vs. S+C; +p<0.05, M+S vs. M+C; §p<0.05, S+C 
vs. M+C on the indicated days; n=17 (S+S and M+C), n=18 (M+S and S+C). (B) 
Cocaine challenge, two-way ANOVA repeated measurements, treatment F3,23=24.58, 
p<0.0001; time F1,23=11.60, p=0.0024; interaction F3,23=0.36, p=0.7831; n=8. Error bars 
indicate SEM. 
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2.2. SAM modifies cocaine-induced gene expression 
An Illumina microarray was used to study persistent changes in gene expression 
in the NAc following repeated SAM and cocaine treatment. The samples for 
gene expression profiling were collected 24 h after the final treatment. Four 
different treatment groups – S+S, M+S, S+C and M+C (4 samples per group) – 
were compared, and differentially expressed genes were identified by a 
combination of statistical significance (p<0.05) and fold change (FC; FC>1.5). 
In total, 482 separate transcripts were expressed differently between the M+S, 
S+C and M+C groups, representing 1.88 % of the total number of transcripts 
analysed whereas 98.12 % of the transcripts remained unaltered. 
To assess the direction of gene expression changes induced by the 
treatments, the M+S, S+C and M+C treatment groups were compared with the 
S+S group. Our data showed that in the M+S group a total of 18 transcripts 
(36%) were up- and 32 transcripts (64%) were downregulated (see Supple-
mentary Tables S1, S2 in Paper II), representing 0.19 % (n=50) of the total 
number of transcripts analysed. In the S+C group, 93 transcripts (38.6%) were 
up- and 148 transcripts (61.4%) were downregulated (see Tables 2, 3 in Paper 
II), representing 0.94% (n=241) of the total number of transcripts analysed. In 
the M+C group, 54 transcripts (42.5%) were up- and 73 transcripts (57.5%) 
downregulated (see Supplementary Tables S3, S4 in Paper II), representing 
0.49% (n=127) of the total number of transcripts analysed.  
Comparisons between M+S, S+C, and M+C groups were also performed. 
Our analysis showed that 28 of 32 (87.5%) SAM-responsive transcripts were 
down- and 9 of 18 (50%) were upregulated in the S+C group (see Supple-
mentary Figures S1A, S2A in Paper II). Comparisons between the M+S and 
M+C groups demonstrated that 12 of 32 (37.5%) SAM-responsive transcripts 
were down- and 8 of 18 (44.4%) were upregulated in the M+C group (see 
Supplementary Figures S1B, S2B in Paper II). Interestingly, we found that 64 
transcripts (43.2%) of the 148 cocaine-responsive genes were down- and 50 
transcripts (53.8%) of the 93 cocaine-responsive genes were upregulated in the 
M+C group (see Supplementary Figures S1C, S2C in Paper II). These data 
suggest that SAM pretreatment reduced 56.8% and 46.2% (of genes down- and 
upregulated by cocaine, respectively) of cocaine-induced transcripts. 
Gene ontology (GO) analysis was performed to group significantly regulated 
genes into similar biological or molecular functional categories. GO analysis 
showed an over-representation of downregulated genes in the M+S, S+C and 
M+C groups encoding proteins involved in: (i) cell cycle, differentiation and 
proliferation, (ii) developmental processes, and (iii) signal transduction (see 
Supplementary Table S5 in Paper II). The upregulated genes in all of those 
groups were primarily aggregated into categories of (i) multicellular organismal 
processes, (ii) cell cycle, differentiation and proliferation, (iii) signal trans-
duction, (iv) developmental processes and/or ion transport (see Supplementary 
Table S6 in Paper II). Table S6 shows that genes involved in “cell-cell sig-
naling” and “behaviour” were upregulated only in the S+C group.  
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2.3. SAM pretreatment alters cocaine-induced CpG-island 
methylation and transcriptional activity in the NAc 
qPCR analysis was performed to validate the subset of gene expression changes 
observed in the microarray analyses. Genes chosen for qPCR validation were 
selected based on their potential roles in cocaine-induced neuronal plasticity 
and on in silico analysis that revealed CpG islands located within their promoter 
regions. From the microarray data conducted on samples from mice treated 
repeatedly with cocaine, 3 genes were selected for validation: a) the down-
regulated genes solute carrier family 17 member 7 or vesicular glutamate 
transporter 1 (Slc17a7) and cholecystokinin (Cck); b) the upregulated gene 
galanin (Gal).  
Using the same RNA samples as used for gene expression profiling, 
transcriptional analysis of Slc17a7 and Cck revealed a significant decrease in 
mRNA levels in the NAc following repeated M+S, S+C or M+C treatments. 
There were significant differences (p<0.001) in both genes between the S+C 
and the M+C groups. Using mouse cerebellum as a reference brain region, we 
found that the selected genes mRNA were altered in the cerebellum also but 
these changes were not as marked as in the NAc. Slc17a7 and Cck mRNA level 
comparisons between both brain tissues demonstrated that Slc17a7 mRNA was 
significantly different (p<0.001) within the S+C group between the NAc and 
cerebellum and that Cck mRNA levels were also different within the S+C and 
M+C groups between the NAc and cerebellum (Figures 17A,B).  
Gal mRNA data from the NAc showed that repeated M+S, S+C and M+C 
treatments increased (p<0.001) Gal expression significantly compared with the 
S+S group. Furthermore, Gal mRNA was significantly different (p<0.001) 
between the S+C and M+C groups. In the cerebellum, we found that M+S and 
S+C treatments (p<0.001) upregulated Gal expression significantly compared 
with the saline control group. There were also statistical differences (p<0.001) 
between S+C and M+C groups. Gal mRNA level comparisons between both 
brain regions demonstrated that there were significant differences (p<0.001) 
within the S+C and M+C groups between the NAc and cerebellum (Figure 
17C).  
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Figure 17. The effect of repeated S-adenosylmethionine (SAM) and cocaine 
administration on selected gene mRNA levels in the mouse NAc (n=8) or cerebellum 
(n=6). (A) Slc17a7 mRNA, two-way ANOVA, treatment F3,44=27.80, p<0.0001; tissue 
effect F1,44=8.44, p=0.0057; interaction F3,44=7.51, p=0.0004; Bonferroni post-hoc test, 
***p<0.001 Saline + Cocaine (S+C) NAc vs. S+C cerebellum; (B) Cck mRNA, 
treatment F3,44=27.67, p<0.0001; tissue effect F1,44=36.35, p<0.0001; interaction 
F3,44=7.66, p=0.0003; Bonferroni post-hoc test, ***p<0.001 S+C and S-adenosyl-
methionine + Cocaine (M+C) NAc vs. S+C and M+C cerebellum; and (C) Gal mRNA, 
treatment F3,44=2045.35, p<0.0001; tissue effect F1,44=1269.06, p<0.0001; interaction 
F3,44=885.82, p<0.0001; Bonferroni post-hoc test, ***p<0.001 S+C and M+C NAc vs. 
S+C and M+C cerebellum. Error bars indicate SEM. 
 
Using a MeDIP assay, Slc17a7, Cck, and Gal promoter-associated CpG-island 
methylation analysis was performed in the NAc tissue. For the Slc17a7 
promoter, MeDIP analysis revealed that both M+S and S+C treatment resulted 
in promoter hypermethylation compared with the S+S group (Figure 18A). We 
also found that repeated SAM pretreatment decreased Slc17a7 promoter 
hypermethylation significantly (p<0.001) compared with the S+C group. With 
regard to Cck promoter methylation, M+S and S+C treatments resulted in 
promoter hypermethylation (Figure 18B). However, there was an additive 
increase in Cck promoter methylation levels in the M+C group compared with 
the S+C group (p<0.001). Gal MeDIP analysis demonstrated that M+S and S+C 
treatments induced promoter-associated CpG-island hypomethylation (Figure 
18C). Remarkably, we found that repeated M+C treatment essentially reversed 
Gal promoter hypomethylation compared with the S+C treatment (p<0.001).  
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Figure 18. The effect of repeated S-adenosylmethionine (SAM) and cocaine treatment 
on selected gene promoter methylation levels in the mouse NAc. (A) Slc17a7 promoter 
methylation, one-way ANOVA, F3,28=1583, p<0.0001; Bonferroni post-hoc test; 
$p<0.05, Saline + Saline (S+S) vs. Saline + S-adenosylmethionine (M+S); *p<0.05, S+S 
vs. Saline + Cocaine (S+C); #p<0.05, S+S vs. S-adenosylmetionine + Cocaine (M+C); 
^p<0.05, M+S vs. S+C; +p<0.05, M+S vs. M+C; §p<0.05, S+C vs. M+C, n=8; (B) Cck 
promoter methylation, F3,28=2587, p<0.0001; Bonferroni post-hoc test; $p<0.05, S+S vs. 
M+S; *p<0.05, S+S vs. S+C; #p<0.05, S+S vs. M+C; ^p<0.05, M+S vs. S+C; +p<0.05, 
M+S vs. M+C; §p<0.05, S+C vs. M+C, n=8; and (C) Gal promoter methylation, 
F3,28=39.58, p<0.0001; Bonferroni post-hoc test, $p<0.05, S+S vs. M+S; *p<0.05, S+S 
vs. S+C; ^p<0.05, M+S vs. S+C; §p<0.05, S+C vs. M+C, n=8. Error bars indicate SEM. 
MeDNA, methylated DNA. 
 
MeDIP data from the mouse cerebellum showed that repeated M+S and S+C 
treatments enhanced (p<0.001, Slc17a7, Cck) promoter-associated CpG island 
methylation significantly (see Supplementary Figures S3A,B in Paper II). 
Moreover, comparisons of Slc17a7 and Cck promoter methylation from both 
brain tissues demonstrated that there were significant differences (p<0.001) 
within the S+C and M+C groups between the NAc and cerebellum. A 
comparison of Gal MeDIP data between both brain regions showed that there 
were significant changes (p<0.001) only within the S+C groups between the 
NAc and cerebellum (see Supplementary Figure S3C in Paper II). 
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2.4. The effect of SAM treatment on methyltransferase activity and 
DNMT-expression in PC12 cells 
To evaluate the underlying mechanism of the SAM modifying effect at the gene 
and genome level, we studied the effects of a single and repeated doses (7 days) 
of 0.5 mM SAM on DNMT activity in PC12 cells. Time-course analyses 
showed that SAM altered methyltransferase activity in a biphasic manner: a 
single SAM treatment (SST) enhanced and a repeated SAM treatment (RST) 
decreased DNMT activity compared with vehicle controls (Figures 19A,B). To 
link methyltransferase activity with Dnmt3a and Dnmt3b mRNA levels, we 
measured the SAM-altered DNMT activity on 1st, 3rd, 5th and 7th treatment days. 
On the 1st day, DNMT activity was similar to vehicle control, on the 3rd day its 
activity was reduced by approximately 50%, on the 5th by 65% and on the 7th 
day by 82% compared with controls (Figure 19C).  
 
 
 
Figure 19. S-adenosylmethionine (SAM) altered DNMT activity in PC12 cells in a 
biphasic manner: (A) a single SAM treatment (SST) enhanced [(two-way ANOVA, 
treatment F1,30=15.64, p=0.0004; time F4,30=6.77, p=0.0005; interaction F4,30=4.91, 
p=0.0037; Bonferroni post-hoc test, $p<0.001 SST SAM 2 h vs. SST control 2 h; n=4) 
whereas (B) repeated SAM treatments (RST) decreased DNMT activity compared with 
controls (two-way ANOVA, treatment F1,30=206.74, p<0.0001; time F4,30=0.18, 
p=0.9461; interaction F4,30=0.13, p=0.9717; n=4)]. (C) The effect of RST SAM 
treatment on DNMT activity in cells, two-way ANOVA, treatment F1,12=141.58, 
p<0.0001; time F3,12=5.65, p=0.0447; interaction F3,12=6.22, p=0.0086; Bonferroni post-
hoc test, $$p<0.001 RST SAM vs. RST control on the indicated days; n=4. Error bars 
indicate SEM. OD, optical density.  
A B 
C 
60 
We found that the decrease in DNMT activity in PC12 cells after repeated SAM 
treatment correlated with downregulation of Dnmt3a mRNA (Figure 20A) but 
not marked with Dnmt3b mRNA levels (Figure 20B). In silico analysis of 
Dnmt3a revealed that CpG islands located within the promoter region; thus, we 
assessed Dnmt3a promoter methylation following repeated SAM treatments. 
The MeDIP results showed that repeated SAM treatment resulted in a 
significant increase in methylation of the Dnmt3a promoter (Figure 20C), 
thereby decreasing Dnmt3a gene transcription in PC12 cells.  
 
 
Figure 20. (A) Repeated S-adenosylmethione (RST SAM) treatments downregulated 
Dnmt3a mRNA levels compared with control groups; two-way ANOVA, treatment 
F1,18=47.49, p<0.0001; time F2,18=1.15, p=0.3391; interaction F2,18=1.15, p=0.3391; n=4. 
(B) The effect of RST SAM treatments on Dnmt3b expression; in each group, n=4. (C) 
RST SAM treatment significantly hypermethylated the Dnmt3a promoter region in PC12 
cells. T-test, ***p=0.0003, n=4. Error bars indicate SEM. MeDNA, methylated DNA.  
 
 
2.5. SAM treatment hypermethylates the Dnmt3a promoter and 
downregulates mRNA levels in the NAc 
To bridge the data from PC12 cell and mice, we assessed Dnmt3a and Dnmt3b 
promoter methylation patterns and transcriptional activity in the NAc. Using 
MeDIP, we discovered that M+S and M+C treatment increased Dnmt3a 
promoter methylation (Figure 21A) but there was no significant change in the 
Dnmt3b promoter (Figure 21B). Using qPCR, our data demonstrated that 
C 
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Dnmt3a mRNA was significantly decreased following M+S and M+C 
treatments and increased following S+C treatment compared with the saline-
treated group (Figure 21C). There were significant (p<0.001) differences in 
both Dnmt3a and Dnmt3b mRNA levels in the NAc after the S+C and M+C 
treatments (Figures 21C,D). These data indicate that repeated SAM treatments 
may decrease methyltransferase activity in vitro and that repeated SAM 
treatments are associated with hypermethylation of the Dnmt3a promoter region 
both in vitro and in vivo. 
 
 
Figure 21. Repeated S-adenosylmethionine (SAM) and cocaine treatment altered DNA 
methylation (A) at the Dnmt3a promoter; one-way ANOVA, F3,28=80.83, p<0.0001; 
Bonferroni post-hoc test, $p<0.05, Saline + Saline (S+S) vs. Saline + S-adeno-
sylmethionine (M+S); #p<0.05, S+S vs. S-adenosylmethionine + Cocaine (M+C); 
^p<0.05, M+S vs. Saline + Cocaine (S+C); +p<0.05, M+S vs. M+C; §p<0.05, S+C vs. 
M+C; n=8; and at the (B) Dnmt3b promoter in the NAc, F3,28=13.04, p<0.0001; 
Bonferroni post-hoc test, *p<0.05, S+S vs. S+C; ^p<0.05, M+S vs. S+C; +p<0.05, M+S 
vs. M+C; n=8. The effect of SAM and cocaine treatment on (C) Dnmt3a mRNA levels; 
one-way ANOVA, F3,28=40.83, p<0.0001; Bonferroni post-hoc test, $p<0.05, S+S vs. 
M+S; *p<0.05, S+S vs. S+C; #p<0.05, S+S vs. M+C; ^p<0.05, M+S vs. S+C; +p<0.05, 
M+S vs. M+C; §p<0.05, S+C vs. M+C; n=8; and (D) on Dnmt3b mRNA level, 
F3,28=35.27, p<0.0001; Bonferroni post-hoc test, *p<0.05, S+S vs. S+C; #p<0.05, S+S 
vs. M+C; ^p<0.05, M+S vs. S+C; +p<0.05, M+S vs. M+C; §p<0.05, S+C vs. M+C; n=8. 
Error bars indicate SEM. MeDNA, methylated DNA.  
 16
62 
3. The role of MS on DNA methylation and  
behavioural changes in rats (Paper III) 
3.1. The effect of MS on exploratory behaviour and  
cocaine-induced behaviour 
Previous studies have demonstrated that MS alters exploratory behaviour in a 
novel environment (Kaneko et al., 1994; Marmendal et al., 2006). To validate 
our model of MS, we first used the exploratory box test to measure novelty-
related behaviour in adult rats. The exploratory box test data demonstrated that 
MS for 180 min per day increased line crossing and the sum of exploratory 
activity in adult rats compared with rats from the AFR group (Figure 22). No 
differences were found between the MS15 and MS180 groups. Based on these 
data, we considered our MS model to be behaviourally valid. 
 
Figure 22. The effect of maternal separation (MS) on exploratory behaviour in adult 
rats. One-way ANOVA followed by Bonferroni post-hoc tests, *p<0.05 animal-facility 
reared (AFR) group vs. MS180 group, n=8. Error bars indicate SEM.  
 
An acute cocaine (10 mg/kg, i.p.) treatment study was performed at PND120–
140. Figure 23A shows that acute cocaine treatment increased locomotor 
activity considerably in both MS groups compared with the control group (two-
way ANOVA repeated measures, MS effect F2,64=2.47, p=0.08; days effect 
F2,64=48.87, p<0.0001; interaction F4,64=4.40, p=0.0033). There were also 
significant differences (p<0.05) between the MS15 and MS180 groups.  
After a daily injection of cocaine over 5 consecutive days (repeated cocaine 
treatment), both MS15 and MS180 rats developed behavioural sensitisation; 
however, there were no significant differences between groups (Figure 23B; 
two-way ANOVA repeated measures, MS effect F2,66=2.23, p=0.124; days 
effect F2,66=7.93, p=0.008; interaction F4,66=0.17, p=0.953). These data indicate 
that MS for 180 min increased the response to acute cocaine treatment and that 
MS enhanced the development of behavioural sensitisation in general when 
compared with AFR adult rats.  
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Figure 23. (A) Maternal separation (MS) was associated with an increased response to 
acute cocaine treatment. Two-way ANOVA repeated measures, Bonferroni post-hoc 
test, **p<0.01 animal-facility reared (AFR) group vs. MS15 or MS180 groups;  
#p<0.05 MS15 vs. MS180, n=13. (B) The effects of repeated cocaine treatments on the 
development of behavioural sensitisation. Two-way ANOVA repeated measures, 
Bonferroni post-hoc test, **p<0.01 MS15 1st day vs. MS15 5th day; *p<0.05 MS180  
1st day vs. MS180 5th day, n=13. Error bars indicate SEM. 
 
 
3.2. MS-induced DNMT upregulation is maintained into adulthood 
To evaluate the role of DNA methylation on MS-induced changes in gene 
expression, we initially assessed the effect of MS on Dnmt1, Dnmt3a and 
Dnmt3b mRNA levels in the NAc of infant (PND15) rats. Using qPCR, we 
found that MS for 15 min per day during the first two weeks of life increased 
Dnmt3b mRNA levels significantly and that MS for 180 min enhanced 
expression levels of all DNMTs in the NAc of PND15 rats (see Supplementary 
Figures S1A-C in Paper III).  
Next, expression levels of DNMTs in the NAc of adult rats (PND120) were 
assessed. We found that DNMTs were significantly upregulated both in the 
MS15 and MS180 groups compared with AFR animals (Figures 24A-C). We 
also found that Dnmt3a and Dnmt3b mRNA levels were significantly different 
(p<0.001) between the MS15 and MS180 groups. To confirm our Dnmt3a 
mRNA results, Western blotting was performed. We found that NAc DNMT3A 
protein levels were increased in MS15 and MS180 adult rats compared with the 
AFR group (Figure 24D) and that there was a significant difference (p<0.01) 
between the MS15 and MS180 groups. These findings indicate that early-life 
stress (MS180) during the first two weeks of life increased Dnmts mRNA levels 
significantly compared with MS15 and AFR groups and that these changes 
persist into adulthood. 
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Figure 24. The effect of maternal separation (MS) on the levels of (A) Dnmt1, 
(B) Dnmt3a and (C) Dnmt3b mRNA in the NAc of adult rats. One-way ANOVA, 
Bonferroni post-hoc test, ***p<0.001 compared with the animal-facility reared (AFR) 
group; #p<0.001 MS15 vs. MS180, n=6. (D) The effect of MS on the protein levels of 
DNMT3A in the NAc of adult rats. One-way ANOVA, Bonferroni post-hoc test, 
***p<0.001 compared with the AFR group; #p<0.01 MS15 vs. MS180, n=6. Error bars 
indicate SEM. OD, optical density. 
 
 
3.3. The effect of MS on global DNA methylation levels  
in the NAc and PFC 
For this part of the study, we assessed whether MS could alter global DNA 
methylation levels in the NAc and in the PFC of adult rats. Global methylation 
analysis (methylated DNA as a percentage of total DNA) showed that DNA 
methylation was significantly decreased in the NAc of MS180 animals (Figure 
25A). We also found that DNA methylation was decreased in the PFC of MS15 
and MS180 animals but that these changes were not statistically significant 
(Figure 25B). These data suggest that MS may alter global DNA methylation 
levels in the NAc of adult rats.  
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Figure 25. (A) The levels of global DNA methylation, shown as percentage methylated 
DNA (5-mC) of total DNA, in the NAc and (B) in the PFC of adult rats. One-way 
ANOVA, Bonferroni post-hoc test, *p<0.05 animal-facility reared (AFR) group vs. 
MS180 group, n=7. 
 
 
3.4. MS is associated with hypermethylation in the PP1c and  
A2AR promoter regions in the NAc 
To investigate the role of MS at a gene level, PP1c and A2AR genes were chosen 
based on both their possible participation in cocaine-induced neuroplasticity 
mechanisms and on data from in silico analysis that revealed CpG islands 
within their promoter regions. We also examined the expression and promoter-
region methylation levels of Reelin (Reln), which is not associated with 
cocaine-induced neuronal plasticity although its promoter is epigenetically 
regulated. Using a MeDIP assay, we measured PP1c promoter-region methy-
lation of PND15 rats. We found that MS15 and MS180 upregulated PP1c 
promoter-region methylation levels significantly (see Supplementary Figure 
S2A in Paper III). To validate the MeDIP results, we used a methylation-
specific qPCR analysis (MSP qPCR). This analysis revealed that methylation of 
the PP1c promoter region was increased in both separated-animal groups at 
PND15 (see Supplementary Figure S2B in Paper III; two-way ANOVA 
repeated measures, treatment F2,30=6.64, p=0.0041; methylation effect 
F1,30=96.78, p<0.0001; interaction F2,30=26.11, p<0.0001). The data from DNA 
methylation analysis correlated with qPCR results because we found that PP1c 
mRNA levels were decreased in the MS180 group compared with control 
animals (see Supplementary Figure S2C in Paper III). 
To determine whether MS-induced PP1c gene promoter-region hypermethy-
lation and transcriptional downregulation is persistent, we examined PP1c 
promoter methylation and transcriptional activity at PND120. Data generated 
using MeDIP and MSP qPCR assays demonstrated that both MS15 and MS180 
elicited DNA hypermethylation at the promoter region of PP1c (Figure 26A 
MeDIP; and Figure 26B; MSP qPCR assay, two-way ANOVA repeated 
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measures, treatment F2,26=15.37, p<0.0001; methylation effect F1,26=94.92, 
p<0.0001; interaction F2,26=36.90, p<0.0001). In correlation with this PP1c 
promoter-region hypermethylation, we found that PP1c mRNA was signi-
ficantly decreased in the NAc of separated rats (Figure 26C).  
 
 
 
Figure 26. (A) A methylated DNA immunoprecipitation (MeDIP) assay showed that 
maternal separation (MS) elicited DNA hypermethylation of the PP1c promoter region; 
one-way ANOVA, Bonferroni post-hoc test, ***p<0.001 compared with the animal-
facility reared (AFR) group; #p<0.001 MS15 vs. MS180, n=6. (B) Methylation-specific 
qPCR showed that MS elicited hypermethylation of the PP1c promoter region. Two-
way ANOVA, Bonferroni post-hoc test, *p<0.05, ***p<0.001 compared with 
methylated or unmethylated DNA of the AFR group, n=6. (C) The effect of MS on 
PP1c mRNA levels, quantified using qPCR. One-way ANOVA, Bonferroni post-hoc 
test, ***p<0.001 compared with the AFR group, n=6. Error bars indicate SEM. M, 
methylated; MeDNA, methylated DNA; U, unmethylated. 
 
The second gene of interest was A2AR. We observed that methylation of A2AR at 
PND15 was enhanced in the NAc of separated animals (see Supplementary 
Figure S3A in Paper III). Quantification of A2AR mRNA by qPCR demonstrated 
that hypermethylation of the A2AR promoter was associated with reduced mRNA 
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levels in MS groups but these data did not achieve statistical significance (see 
Supplementary Figure S3B in Paper III). 
To assess whether MS-induced A2AR hypermethylation was persistent, we 
evaluated promoter methylation and mRNA at PND120. MeDIP results showed 
that changes in DNA methylation at the A2AR promoter is maintained into 
adulthood (Figure 27A). Furthermore, we found that A2AR hypermethylation 
was statistically different (p<0.001) between MS15 and MS180 animals. We 
also found that hypermethylation of the A2AR promoter lead to reduced mRNA 
in the MS180 group (Figure 27B). There were also significant differences 
(p<0.05) between the MS15 and MS180 groups. Thus, these data suggest that 
MS during the first two weeks of life results in persistent PP1c and A2AR 
promoter-region hypermethylation and transcriptional downregulation in the 
NAc. However, neither handling nor MS affected Reln promoter-region 
methylation or mRNA in the NAc (data not shown). 
 
  
Figure 27. Maternal separation (MS) was associated with A2AR promoter methylation 
and transcriptional downregulation in the NAc of adult rats. (A) A methylated DNA 
immunoprecipitation (MeDIP) assay showed that MS elicited DNA hypermethylation of 
the A2AR promoter region. One-way ANOVA, Bonferroni post-hoc test, ***p<0.001 
animal-facility reared (AFR) group vs. MS15 or MS180 groups; #p<0.001 MS15 vs. 
MS180, n=6. (B) The effect of MS on mRNA levels of the A2AR gene. One-way 
ANOVA, Bonferroni post-hoc test, ***p<0.001 AFR vs. MS180, #p<0.05 MS15 vs. 
MS180, n=6. Error bars indicate SEM. MeDNA, methylated DNA. 
 
To determine whether the PP1c and A2AR promoter-region hypermethylation 
and transcriptional downregulation is NAc-specific, the PFC of adult rats was 
studied. Our data showed that neither handling nor MS affected PP1c or A2AR 
mRNA or promoter methylation levels in the PFC (see Supplementary Figures 
S4A,B; S5A,B in Paper III). There were also no changes in Reln mRNA or 
promoter-methylation levels in the PFC of MS15 and MS180 animals (Fig. 
S4C; S5C). These data indicate that PP1c and A2AR mRNA and promoter 
methylation changes after MS are NAc-specific.  
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DISCUSSION 
1. The role of DNA methylation on cocaine-induced 
behavioural sensitisation in mice (Paper I) 
In study I, our aim was to investigate the role of cocaine treatment on the 
expression of DNMTs and selected genes (PP1c, fosB) in the NAc of adult 
mice; and to assess the effect of a DNMT inhibitor on cocaine-induced gene 
expression changes and the development of behavioural sensitisation in mice. 
 
 
1.1. The role of DNMT on cocaine-induced behavioural sensitisation  
Previous findings have implied that the function of DNMTs in the central 
nervous system (CNS) may include DNA repair and neurodegeneration (Brooks 
et al., 1996; Endres et al., 2000 and 2001; Fan et al., 2001) and that the mis-
regulation of DNA methylation and DNMTs may be involved in cognitive 
disorders such as schizophrenia, Rett syndrome, and Fragile X mental 
retardation (Sutcliffe et al., 1992; Amir et al., 1999; Veldic et al., 2004). 
Studies by Miller and Sweatt (2007) have demonstrated that DNA 
methylation levels were rapidly and dynamically regulated in the hippocampus 
following the associative training paradigm of contextual fear conditioning. 
They found that Dnmt3a and Dnmt3b mRNA levels were upregulated in the 
CA1 area of the hippocampus following fear conditioning (Miller and Sweatt, 
2007). Our data showed that acute cocaine treatment upregulated Dnmt3a and 
Dnmt3b mRNA levels in the NAc and hippocampus (Figures 8B,C and 9B,C; 
respectively). In addition, we found that Dnmt3a expression achieved the 
highest level after acute cocaine treatment and that it diminished after repeated 
cocaine exposure. With respect to Dnmt3a and Dnmt3b expression levels in the 
NAc, cocaine-induced changes in the hippocampus were more dynamic as there 
were no significant changes at 24 h after treatment. However, neither acute nor 
repeated cocaine treatment altered Dnmt1 mRNA levels in the NAc or 
hippocampus; thus, we hypothesize that cocaine induces de novo DNA methy-
lation. 
Currently, the signal transduction processes that control cocaine-induced 
DNMTs expression in the adult CNS are unknown. Although DNA methylation 
form part of the regulation of gene expression, it infers that there may be some 
overlap in intracellular signaling pathways with other chromatin modification 
mechanisms. In the adult CNS chromatin modification is governed by various 
intracellular signaling pathways, including the Ras-mitogen-activated protein 
kinase (MAPK/ERK) cascade (Renthal and Nestler, 2008; Brami-Cherrier et al., 
2009). It has been found that targeting the Ras signaling pathway with drugs, 
such as methotrexate and inhibitors of MAPK/ERK, decreases DNA 
methylation in malignant hematological diseases and colon cancer cells, 
indicating a causal relationship between Ras signaling and DNA methylation 
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(MacLeod et al., 1995; Philips, 2004; Diaz-Flores and Shannon, 2007; Lu et al., 
2007; Morgan et al., 2007). 
 In recent years, the MAPK/ERK signaling cascade has been implicated in 
responses to most drugs of abuse (Berke and Hyman, 2000; Nestler, 2001; 
Fasano and Brambilla, 2002; Girault et al., 2007). It has been found that in 
response to cocaine, MAPK/ERK and the downstream MSK1 controls an early 
phase of histone H3 phosphorylation at the c-fos promoter in striatal neurons 
(Brami-Cherrier et al., 2005). MSK1 action may be potentiated by the 
concomitant inhibition of PP1 by nuclear translocation of the dopamine and 
cAMP-regulated phosphoprotein 32 kDa (DARPP-32; Stipanovich et al., 2008; 
Brami-Cherrier et al., 2009). Cocaine also phosphorylates the transcription 
factor CREB via the MAPK/ERK–MSK1 cascade (Swank and Sweatt, 2001; 
Levine et al., 2005). As discussed above, phosphorylation and activation of 
CREB recruits CBP, which regulates chromatin structure as part of CREB-
dependent activation of nuclear gene transcription (Sweatt, 2009). Therefore, 
we speculate that cocaine-induced activation of the Ras signaling pathway may 
trigger both DNA methylation and histone modifications.  
 
 
1.2. DNA methylation regulates PP1c and fosB transcription  
in the NAc after acute and repeated cocaine treatment 
As we found that cocaine treatment significantly upregulated Dnmt3a and 
Dnmt3b expression in the NAc and thereby may induce hypermethylation of 
certain genes promoters, we evaluated PP1c and fosB promoter-region methy-
lation and mRNA levels in the NAc of mice. Our data demonstrated that DNMT 
activation results in hypermethylation of the PP1c promoter region after acute 
and repeated cocaine treatment (Figures 11B,C), increased MeCP2 binding in 
the PP1c promoter region (Figure 13A) and decreased PP1c expression at both 
the mRNA and protein level (Figures 10A,B). It has been shown that 
methylation of DNA brings about a general deacetylation of histones H3 and 
H4, prevents methylation at histone H3 lysine K4 and induces methylation of 
histone H3 lysine K9 (Kouzarides, 2007; Li et al., 2007; Shahbazian and 
Grunstein, 2007; Patra and Szyf, 2008). Based on these data, we speculate that 
MeCP2 can recruit co-repressor complexes to methylated PP1c promoter 
regions including histone-modifying enzymes, such as HDACs and HMTs. 
Repression of PP1c may result in several effects at the intracellular signal 
transduction level. For example, inhibition of PP1 has been shown to increase 
phosphorylation of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptor subunit GluR1 and Ca2+/calmodulin-dependent protein 
kinase II (Genoux et al., 2002). Reduced PP1 may have important effects for 
transcriptional regulation by CREB via the ability of PP1 to complex with 
HDAC. Canettieri and colleagues (2003) have demonstrated that a HDAC1-PP1 
complex represses CREB activation under basal conditions and dephosphory-
lates CREB to return the system to baseline following stimulation (Canettieri et 
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al., 2003). These data suggest that repression of PP1 is crucial for providing 
phosphorylated CREB with the capacity to recruit CBP to the promoter, at 
which time histones are acetylated and help drive the transcription of particular 
genes. Thus, repression of the PP1c gene via methylation of its promoter 
regions should allow aberrant phosphorylation of crucial receptors, protein 
kinases and transcription factors during cocaine-induced neuroadaptation. 
Previous studies have demonstrated that the expression of Fos-family 
proteins (c-fos, fosB, fra-1, and fra2) is induced rapidly in the NAc after acute 
exposure to drugs of abuse (Hope et al, 1994). This induction is transient, 
lasting only 4-12 h after drug exposure. In our study, we found that cocaine 
treatment hypomethylated the fosB promoter (Figure 12B), decreased MeCP2 
binding in the fosB promoter region (Figure 13B) and increased fosB mRNA 
levels (Figure 10C). These data suggest that cocaine may also induce DNA 
demethylation, thereby increasing the transcription of particular genes. 
However, in contrast with the large amount of information that has accumulated 
on DNA methylation, DNA demethylation remains quite controversial and a 
largely unresolved area of research, and there is no consensus on DNA 
demethylases in mammalian cells although several potential canditates have 
been proposed (Métivier et al., 2008; Ooi and Bestor, 2008).  
 
 
1.3. DNMT inhibition by zebularine delays the development  
of cocaine-induced behavioural sensitisation 
The effect of the DNMT inhibitor zebularine on cocaine-induced molecular 
changes and the development of behavioural sensitisation were assessed. Our 
data showed that zebularine blocked hypermethylation in the PP1c promoter 
region and delayed the development of cocaine-induced behavioural sensi-
tisation. The decrease in PP1c hypermethylation was triggered using an i.c.v. 
infusion of zebularine and it was sufficient to re-establish PP1c gene expression 
in the NAc. It has been found that zebularine is a potent inhibitor that affects all 
DNMT subtypes (Weisenberger et al., 2004; Marquez et al., 2005). However, 
we were unable to determine the DNMT subtype important for the development 
of behavioural sensitisation. It is possible that both DNMT3A and DNMT3B 
work together to hypermethylate the promoter-associated CpG islands and to 
then transcriptionally repress these genes, aiding in the development of 
behavioural sensitisation. 
In Figure 14A we show that a single dose of zebularine caused hypo-
methylation in the promoter of PP1c at 1.5 h after treatment. However, the 
effect of repeated zebularine (Z+S) administrations resulted in PP1c promoter-
region hypermethylation at 24 h after the last treatment (Figures 15A,B). Based 
on zebularine pharmacokinetics, the plasma zebularine concentration in mice 
declines with a terminal half-life (t1/2) of 40 min after an intravenous (i.v.) 
injection of 100 mg/kg (Holleran et al., 2005). We speculate that at 24 h after 
the last administration of zebularine (Z+S), the DNMT inhibitory effect has 
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ended. Therefore, it is possible that the slight increase in methylation in the 
PP1c promoter-associated CpG islands in the Z+S groups (Figures 15A,B) is 
due to a compensatory increase in DNMT activity after zebularine inhibition. 
Despite this slight hypermethylation in the PP1c promoter region after Z+S 
treatment, we found that PP1c mRNA levels were increased approximately  
1.5-fold in the Z+S group compared with the saline control (S+S, Figure 15C) 
suggesting that smaller changes in DNA methylation may not alter gene 
transcription. Repeated Z+C co-treatment data demonstrated that zebularine 
treatment blocked PP1c promoter-region hypermethylation (Figures 15A,B), 
which was associated with an enhanced PP1c mRNA level (Figure 15C). We 
speculate that in addition to PP1c, zebularine may also inhibit hypermethylation 
in promoter-associated CpG islands of other genes, re-establish the transcription 
of these genes and therefore inhibit cocaine-induced neuroplasticity in the brain. 
At the behavioural level, we found that repeated Z+C co-treatment delayed 
the development of behavioural sensitisation although zebularine (Z+S) itself 
did not affect locomotor activity. Interestingly, zebularine did not modify the 
acute cocaine effect, suggesting that the promoter-region hypermethylation may 
be an important underlying mechanism of the altered gene expression during the 
development of behavioural sensitisation. Therefore, we hypothesize that 
zebularine, via normalization of gene transcription at the cellular level, stabi-
lized neuronal network function and therefore delayed the development of 
psychostimulant-induced behavioural sensitisation. As DNA methylation plays 
an important role in learning and memory formation (Miller and Sweatt, 2007), 
zebularine may also delay cocaine-induced behavioural sensitisation by inhi-
biting DNA methylation in the hippocampus and altering cocaine-environment 
associated learning and memory formation. 
 
 
2. The role of SAM in cocaine-induced DNA methylation 
and behavioural sensitisation in mice (Paper II) 
In this study, we assessed the role of the methyl donor SAM on cocaine-induced 
gene expression changes and the development of behavioural sensitisation in 
mice. 
 
 
2.1. The effect of SAM treatment on cocaine-induced gene 
expression and CpG-island methylation 
Using whole-genome gene expression analysis, our data demonstrated that 
repeated SAM treatments altered 50 transcripts significantly. Of these trans-
cripts, 36% were upregulated and 64% were downregulated suggesting that 
treatment with exogenous SAM primarily silences gene expression, as expected 
from the typical silencing effect of DNA hypermethylation. Compared with 
SAM, cocaine treatment has a broader impact upon gene expression. Repeated 
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cocaine treatments changed 241 transcripts and predominantly downregulated 
these transcripts. Thirty seven transcripts of the 50 SAM-responsive genes were 
also altered in the S+C group. Interestingly, the number of significantly affected 
genes in the M+C group was lower than in the S+C group. These data 
demonstrate that 46% and 57% (respectively up- and downregulated) SAM and 
cocaine treatment-group transcripts were no longer significantly different 
compared with the respective transcripts from the S+C group, suggesting that 
SAM pretreatment modified the cocaine-induced gene expression pattern in the 
NAc. GO analysis revealed that SAM pretreatment decreased the expression of 
several cocaine-induced genes in different functional groups, demonstrating that 
SAM’s blunting effect is non-specific.  
Other microarray studies have demonstrated that several genes are affected 
by cocaine (S+C) treatment (Freeman et al., 2010; Rodríguez-Borrero et al., 
2010; Maze and Nestler, 2011). However, there have been only a few reports 
demonstrating an effect of SAM or MET (a precursor of SAM) at the genome 
level. In SK-N-BE neuroblastoma cells, SAM modulates 7 genes (of a total of 
588 genes analysed), of which 3 were upregulated and 4 downregulated, 
showing low levels of modulation (Cavallaro et al., 2006). Weaver and 
colleagues (2006) demonstrated that repeated MET intraventricular treatments 
altered 337 transcripts, representing 1.08% of the population of genes on the 
DNA microarray, and of these altered transcripts, 217 (64%) were down-
regulated and 120 (35.6%) were upregulated in the rat hippocampus (Weaver et 
al., 2006). It is difficult to compare our results with these data but nevertheless, 
the ratio of up- and downregulated genes is similar between all of the studies. 
Both SAM and MET affect the expression of a limited number of genes and do 
not affect the vast majority of the genome, suggesting that SAM or MET 
treatments, despite their global nature, do not result in a general silencing of 
gene expression. The basis for the specificity of SAM or MET gene expression 
effects remains unknown. Thus, treatment with exogenous SAM induces minor 
effects on whole-genome gene expression; however, SAM pretreatment 
significantly modified cocaine-induced gene expression by blunting non-
specifically the cocaine response. 
To determine the effect of SAM and cocaine at the gene level, we selected 
(from the gene expression profiling data) Cck, Slc17a7, and Gal genes for 
analysis based on their possible participation in cocaine-induced neuro-
adaptations in the NAc (Hökfelt et al., 1980; Josselyn et al., 1997; Fremeau et 
al., 2001; Narasimhaiah et al., 2009). We found that repeated SAM treatments 
caused both hypermethylation and hypomethylation in the promoter regions of 
the selected genes, and these changes associated with down- and upregulated 
mRNA expression, respectively (Figures 17A-C; 18A-C; see supplementary 
Figures S3A-C in Paper II). These results are comparable in part with the 
studies that demonstrated that treatment with exogenous SAM elicits gene 
silencing via promoter hypermethylation (Watson et al., 1999; Fuso et al., 2001; 
Pulukuri et al., 2007). Similarly, repeated treatments with MET is also 
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associated with hypermethylation of the Reln and glutamate decarboxylase 67 
(Gad67) promoter regions in mouse frontal cortex and striatum (Tremolizzo et 
al., 2002; Dong et al., 2008). We also found that SAM pretreatment inhibited 
cocaine-induced hyper- and hypomethylation (Slc17a7 and Gal, respectively) in 
the NAc. Interestingly, SAM additively enhanced cocaine-induced hyper-
methylation at the Cck promoter, which was associated with Cck transcriptional 
downregulation in the NAc (Figures 17B and 18B). Thus, it appears that SAM 
pretreatment may both increase and decrease cocaine-induced DNA methylation 
at a gene level.  
To evaluate whether the effects of SAM are NAc-specific or not, we 
assessed the expression of the selected genes and promoter-region methylation 
levels in the mouse cerebellum. Our data showed that repeated SAM treatment 
changed Slc17a7 and Cck promoter methylation levels significantly in both 
brain regions (see supplementary Figures S3A,B in Paper II) indicating that 
SAM effects are rather non-specific. As expected, the cocaine effects on the 
gene expression were more prominent in the NAc than in the cerebellum. These 
data suggest that SAM treatment modifies cocaine- (another epigenetic factor) 
specific effects in the NAc.  
 
 
2.2. The effect of SAM on DNMT expression and  
methyltransferase activity 
In this part of the study, we analysed the consequences of acute and repeated 
SAM treatments on DNMTs expression and methyltransferase activity in PC12 
cells. We found that treatment with exogenous SAM induced a biphasic effect 
on methyltransferase activity (Figures 19A,B) because a single SAM treatment 
enhanced whereas repeated daily treatments significantly reduced methyl-
transferase activity. Both in vitro and in vivo data show that repeated SAM 
treatments increases Dnmt3a promoter-region hypermethylation, which is 
associated with downregulation of Dnmt3a mRNA (Figures 20A,C and 21A,C). 
SAM and cocaine co-treatment (M+C) also increased Dnmt3a promoter 
methylation compared with the S+C group. As we found significantly down-
regulated Dnmt3b mRNA levels in the M+C group (Figure 21D), without 
methylation of the Dnmt3b promoter, we speculate that SAM-induced histone 
methylation may be involved in Dnmt3b expression. Moreover, based on 
accumulating data, we propose the following model for the regulation of DNA 
methylation/demethylation activities. A single dose of SAM stimulates methyl-
transferase activity resulting in increased DNA methylation. It is possible that 
SAM increases DNA methylation by also decreasing demethylation via 
inhibition of MBD2 (Detich et al., 2003). Repeated administration of exogenous 
SAM decreases methyltransferase activity via decreased Dnmt3a and Dnmt3b 
expression and via increased levels of intracellular SAH, which inhibits DNMT 
activity and is the product of the transmethylation reactions (Chiang, 1998). 
Therefore, we propose that the modifing effect on cocaine-induced gene 
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expression in the NAc following repeated SAM treatment may result from an 
altered balance between methylation/demethylation activities. We also speculate 
that the decrease in SAM-induced methyltransferase activity is reversible after 
discontinuing treatment with exogenous SAM. Although we found that SAM 
and cocaine treatment may also cause promoter-associated CpG-island hyper-
methylation (e.g., Cck), we speculate that other factor(s) may participate in fine-
tuning the balance in DNA methylation/demethylation. 
 
 
2.3. The effect of SAM treatment on cocaine-induced  
behavioural sensitisation 
At the behavioural level, we found that repeated SAM treatment alone did not 
affect locomotor activity (Figure 16A); a related finding has been described 
following repeated MET treatment (Tremolizzo et al., 2002). Several recent 
studies indicate that injections of DNMT inhibitors into different brain regions 
may affect inversely the development of cocaine-induced behavioural sensi-
tisation and CPP in mice. For example, continuous intra-NAc infusion of 
RG108 over the 7 days increased cocaine-induced CPP and enhanced the 
induction of behavioural sensitisation to chronic cocaine (LaPlant et al., 2010). 
Injections of the DNMT inhibitor 5-aza into hippocampus CA1 area prevented 
the acquisition of cocaine-induced CPP; however 5-aza had no effect on 
acquisition after injection into the prelimbic cortex (Han et al., 2010). We 
previously demonstrated that repeated zebularine i.c.v. injections decreased 
cocaine-induced behavioural sensitisation, suggesting that zebularine (due to 
diffusion into brain tissue) affected DNMT activity in the hippocampus to a 
greater extent than the NAc (Paper I). In this study, we found that SAM 
pretreatment significantly potentiated cocaine-induced ambulations during the 
development and expression of behavioural sensitisation in mice. Therefore, our 
behavioural data, coupled with the decreased Dnmt3a and Dnmt3b mRNA 
levels in the NAc, support the findings that decreased methyltransferase activity 
in the NAc positively regulates cocaine-induced behavioural sensitisation 
(LaPlant et al., 2010). Increased locomotor activity in the M+C group on 
treatment days 5–7 is also consistent with the decreased Dnmt3a mRNA level 
and methyltransferase activity in PC12 cells (Figures 19C and 20A). It is not 
known how treatment with exogenous SAM affects Dnmt3a and Dnmt3b 
expression in other brain regions; however, we speculate that reduced Dnmt3a 
and Dnmt3b expression in the NAc may have a greater impact on cocaine-
induced locomotor activity compared with other brain regions (e.g., CA1 area).  
The cocaine challenge study suggests that increased locomotor activity in the 
M+C group (compared with the S+C group) is persistent indicating that the 
effects of SAM on cocaine are long-lasting even after a period of cocaine 
withdrawal. Recently, it has been reported that chronic MET (0.78 g/kg, twice 
per day subcutaneously) diminished the rewarding effects of cocaine in the CPP 
procedure (LaPlant et al., 2010). There are a number of methodological 
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differences between the LaPlant study and our study that could account for 
these disparate findings including the drugs (MET vs. SAM), doses of MET and 
SAM, and the different pretreatment regimens. We think that an especially 
important factor is the pretreatment regimen as SAM or MET may affect 
different genes depending on the interval between pretreatment and cocaine 
administration. However, our data indicate that the methyl donor SAM modifies 
cocaine-induced gene expression in the NAc of mice and thereby contributes to 
the development of behavioural sensitisation.  
 
 
3. The role of MS in DNA methylation and  
behavioural changes (Paper III) 
Using MS as an early-life stress model, our aim was to investigate whether MS 
in rats could alter the expression of DNMTs and selected genes (PP1c, A2AR) in 
the NAc of infant and adult rats and whether these changes were associated with 
the development of cocaine-induced behavioural sensitisation in adulthood. 
 
 
3.1. The effect of MS on exploratory behaviour and  
cocaine-induced behaviour in adult rats 
To validate our model of MS, we used the exploratory box test to measure 
novelty-related behaviour in adult rats subjected to MS manipulation. 
Exploratory behaviour in novel environments is influenced by the conflicting 
motivators fear and curiosity. Mällo and colleagues (2007) found that animals 
with a high motivation to explore displayed reduced anxiety-like behaviour 
(Mällo et al., 2007). It has also been reported that chronic variable stress 
increased exploratory activity in the exploratory box test and increased 
dopamine D1 receptor-specific cAMP accumulation in the NAc of rats (Matrov 
et al., 2011). Our data demonstrated that in the adult MS180 group, rats showed 
increased exploratory activity compared with the AFR and MS15 groups. These 
data were consistent with the Marmendal et al. (2006) study, where early 
deprivation was found to increase exploratory behaviour in adult male Wistar 
offspring. The exploratory box test data are also consistent with our cocaine 
results, and several studies have demonstrated that there is a significant 
correlation between a subject's locomotor response to a novel environment and 
its locomotor response to cocaine (Hooks et al., 1991; Bardo et al., 1996). There 
is a report demonstrating that exposure to novelty activates, at least in part, the 
same neural substrate that mediates the rewarding effects of drugs of abuse 
(Bardo et al., 1996); however, the exact mechanism underlying the effects of 
MS on exploratory behaviour is unknown.  
The acute cocaine treatment (10 mg/kg, i.p.) study demonstrated that adult 
rats from the MS180 group showed an increased response to acute cocaine 
treatment (Figure 23A), suggesting that the duration of MS affected this result. 
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The repeated cocaine treatment study indicates that the early-life stress (both 
handling and MS) increased susceptibility to cocaine-induced behavioural 
sensitisation in adult animals compared with the AFR group (Figure 23B). Few 
studies have investigated the influence of MS on the effects of cocaine. For 
example, Li and colleagues (2003) observed that in adulthood, AFR, MS15 and 
MS180 groups did not differ in their locomotor responses to an acute 
intravenous cocaine treatment and that MS15 and MS180 groups showed 
significantly less robust effects of cocaine challenge than rats from an AFR 
group; however, they used only female rats (Li et al., 2003). Kikusui and 
colleagues (2005) found that repeated MS increased the hyperlocomotor 
response to 10.0 mg/kg cocaine regardless of mouse gender (Kikusui et al., 
2005). Marin and Planeta (2004) found that male adolescent rats exposed to MS 
exhibited an increased locomotor response to cocaine; however, this response 
was not observed in adult rats (Marin and Planeta, 2004). Brake and colleagues 
(2004) demonstrated that MS and non-handled animals displayed a dose-
dependent increased sensitivity to cocaine-induced locomotor activity compared 
with a handled group (Brake et al., 2004). These data suggest that the outcome 
of the model of early-life stress may depend on various factors, such as 
environmental conditions, gender, specifics of the separation procedure and the 
duration of separation, among others. 
 
 
3.2. The effect of MS on the expression of DNMT and  
selected genes  
In this study, we showed that early-life stress upregulated DNMTs expression in 
the NAc of infant rats and that this upregulation persisted into adulthood. We 
found that MS increased expression levels of Dnmt3a primarily, suggesting that 
de novo methylation dominated. The signal transduction processes that control 
MS-induced DNMTs expression in the infant CNS are unknown. As we found 
upregulated Dnmt3a mRNA levels in the NAc, we hypothesized that increased 
GR stimulation by corticosterone during MS could trigger a cascade of 
molecular events, which continually increases DNMTs expression in the brain. 
These changes facilitate adaptation to acute environmental challenges but may 
lead to behavioural pathologies in chronic stress conditions.  
On a global level, we found that MS significantly decreased DNA methy-
lation in the NAc but not the PFC of adult rats (Figure 25). There is a limited 
number of studies that describe MS-induced DNA methylation on a global level 
in the rat brain. Using mild and high prenatal stress, Mychasiuk et al. (2011) 
found that mild prenatal stress increased and high prenatal stress decreased 
global DNA methylation levels in the frontal cortex and hippocampus of rat 
offspring.  
Studies have demonstrated that stressful experiences during early life may 
cause both DNA hypo- and hypermethylation of specific gene promoters 
(Weaver et al., 2004; Fuchikami et al., 2009; Murgatroyd et al., 2009; Roth et 
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al. 2009; Franklin et al., 2010). We found that MS was associated with hyper-
methylation and transcriptional downregulation of the PP1c and A2AR promoter 
regions in the NAc but not the PFC. Neither handling nor MS affected Reln 
promoter-region methylation or transcription levels in the NAc and PFC. These 
data suggest that MS effects may be gene- and brain-region specific. Moreover, 
because we found that on global level MS was associated with DNA 
hypomethylation and at gene level with DNA hypermethylation, our findings 
suggest that MS may regulate DNA methylation at different levels – on a global 
and a gene level. However, the exact mechanisms underlying these changes are 
unknown. A similar phenomenon – global DNA hypomethylation and gene-
specific hypermethylation – has been observed in aging-related conditions 
(Wilson et al., 1987; Oakes et al., 2003; Calvanese et al., 2009). Furthermore, in 
many complex diseases including cancer, atherosclerosis and psychiatric dis-
orders (Baylin and Herman, 2000; Pogribny and Beland, 2009), it is common to 
observe global DNA hypomethylation and gene-specific hypermethylation (Kile 
et al., 2010). 
As mentioned above, gene expression analysis showed that MS induced 
persistent transcriptional downregulation of the neuronal plasticity-related genes 
PP1c and A2AR in the NAc. The PP1 enzyme contains both a catalytic subunit 
and a regulatory subunit (Goldberg et al., 1995). Protein kinase A and PP1 regu-
late the phosphorylation state and activity of many physiological effectors 
including neurotransmitter receptors, for example the AMPA receptor, that 
regulate the excitability of medium spiny neurons (Yan et al., 1999). Repression 
of the PP1c gene via hypermethylation of its promoter region could enable 
aberrant phosphorylation of crucial receptors and transcription factors during 
and after MS. Our data suggest that environmental factors, MS and cocaine 
treatment (cocaine resulted in PP1c promoter hypermethylation and transcrip-
tional downregulation in the NAc of mice, Paper I) have a similar effects on 
PP1c promoter methylation and transcription activity in the NAc. 
The activity of the A2AR determines the response to acute cocaine treatment. 
NAc contains a high density of A2ARs, which pre- and postsynaptically regulate 
glutamatergic and dopaminergic neurotransmission on GABAergic striatal 
efferent neurons, in part by acting on heteromers of adenosine receptors with 
dopamine and metabotropic glutamate receptors (Ferré et al., 2007). At the 
behavioural level, pharmacological blockade typically potentiates the acute 
behavioural effects of psychostimulants by acting on the NAc A2ARs (Popoli et 
al., 1998; Filip et al., 2006). These finding are consistent with our results that 
demonstrate that reduced A2AR mRNA levels in the NAc of MS180 rats is 
associated with an enhanced response to acute cocaine treatment.  
Thus, we conclude that stressful experiences in early life may create a 
background, via aberrant DNA methylation, that promotes the development of 
cocaine-induced behavioural sensitisation in adult rats. 
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CONCLUSIONS 
1. Our data demonstrated that cocaine treatment caused a dynamic increase in 
Dnmt3a and Dnmt3b expression levels in the NAc and hippocampus 
suggesting that cocaine induces de novo DNA methylation. At the gene 
level, we determined that cocaine treatment induced both DNA methylation/ 
demethylation thereby affecting the transcription of particular genes. Intra-
cerebroventricular treatment with the DNMT inhibitor zebularine normalised 
hypermethylated gene transcription and delayed the development of cocaine-
induced behavioural sensitisation in adult mice indicating that DNA 
methylation/ demethylation activities may be important processes during the 
development of behavioural sensitisation in adult mice. 
 
2. The methyl donor SAM modified cocaine-induced gene expression at the 
genome and gene level in the NAc and may thereby contribute to the 
development of cocaine-induced behavioural sensitisation in adult mice.  
 
3. Maternal separation may cause, via aberrant DNA methylation, persistent 
changes in gene expression and create a background that promotes the 
development of cocaine-induced behavioural sensitisation in adult rats. 
 
In summary, our results suggest that DNA methylation plays an important role 
in the development of cocaine-induced behavioural sensitisation. Furthermore, 
environmental factors, such as SAM and early-life stress, may promote, via 
DNA methylation, the development of psychostimulant-induced drug addiction 
in mice and rats.  
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SUMMARY IN ESTONIAN 
DNA metüülimise roll kokaiini poolt põhjustatud käitumusliku 
sensitisatsiooni kujunemises  
Ravimsõltuvust defineeritakse kui kroonilist psüühika- ja käitumishäiret, mille 
peamiseks iseloomustajaks on vastupandamatu tung tarbida psühhotroopseid 
aineid hoolimata sellega kaasuvatest tõsistest kõrvaltoimetest (Kalivas et al., 
2005; Hyman et al., 2006; Koob and Kreek, 2007). Eksperimentaalsed uuringud 
on näidanud, et ravimsõltuvus kujuneb välja järk-järgult ja sõltuvusega seotud 
neurobioloogilised muutused võivad jääda püsima ka pärast psühhotroopsete 
ainete tarvitamise lõppu. Ulatuslikud epidemioloogilised uuringud on näidanud, 
et ravimsõltuvuse kujunemisel on oluline roll nii geneetilisel eelsoodumusel kui 
ka keskkonnateguritel (Nestler, 2001; Goldman et al., 2005; Hyman et al., 
2006). 
Geenid, mis võivad suurendada riski ravimsõltuvuse tekkeks, on käesoleval 
ajal teadmata. Uuringud on näidanud, et ravimsõltuvuse teket saab mõjutada 
erinevate keskkonnateguritega nagu stress, psühhotroopsete ainete kättesaada-
vus, varajase eluea keskkond (Nestler, 2001; Weaver et al., 2004; Goldman et 
al., 2005; Waterland et al., 2006; Szyf, 2009). Hüpoteesi kohaselt peavad 
püsivate käitumuslike muutuste aluseks olema püsivad muutused geeniekspres-
sioonis. Seetõttu on viimasel ajal üha enam hakatud tähelepanu pöörama epi-
geneetikale, mis kirjeldab geeniekspressiooni regulatsioonis osalevaid moleku-
laarseid mehhanisme ning keskkonna ja geenide vahelisi seoseid.  
Geeniekspressiooni reguleerimiseks on vajalik, et vastav geen oleks trans-
kriptsiooni läbiviivatele valkudele kättesaadav. Rakutuumas olev DNA on 
kokkupakitud kromatiiniks, mis on DNA, histoonide ja teiste valkude komp-
leks. Kromatiini piirkonnas, kus ei toimu transkriptsiooni (heterokromatiin) on 
DNA tihedalt seotud histoonidega pärssides transkriptsiooni läbiviivate valkude 
(nt. RNA polümeraas II) seostumist DNA-ga (Fischle et al. 2003). Kromatiini 
osa, mis on vähem kokkupakitud ning kus toimub geenide transkriptsioon, 
nimetatakse eukromatiiniks. Epigeneetilised mehhanismid nagu histoonide 
modifitseerimine, DNA metüülimine ja mikroRNA-d, on olulised mehhanismid 
geeniekspressiooni regulatsioonis. Häired epigeneetilistes mehhanismides või-
vad põhjustada tõsiseid patoloogiaid nagu näiteks kasvajate teket, arengu- ja 
psühhiaatrilisi häireid (Rett sündroom, Fragiilse X-i sündroom, autism, 
depressioon, ärevus) jne. 
Korduv psühhostimulaatori (nt. kokaiini või amfetamiini) manustamine 
põhjustab katseloomadel suurenenud käitumusliku vastuse. Sellist fenomeni 
nimetatakse psühhomotoorseks ehk käitumuslikuks sensitisatsiooniks ning see 
modelleerib adiktiivset käitumist ja psühhostimulaatorite psühhootilisi komp-
likatsioone inimesel (Robinson and Berridge, 1993; Pierce and Kalivas, 1997). 
Käitumusliku sensitisatsiooni tekke ja avaldumisega on seotud aju sarrustuse 
piirkonnad nagu naalduv tuum (nucleus accumbens) ja prefrontaalne korteks. 
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Kuna käitumuslikule sensitisatsioonile on iseloomulikud püsivad muutused 
katseloomade käitumises, siis arvatakse, et osaliselt on selle põhjuseks lühi- ja 
pikaajalised geeniekspressiooni muutused, mis omakorda mõjutavad närvi-
impulsi ülekannet, sünapsite moodustamist ja närviringide funktsioneerimist.  
Mitmed uuringud viitavad, et epigeneetilised mehhanismid (eriti geeni pro-
mootori piirkonna DNA metüülimine) on seotud pikaajaliste geeniekspressiooni 
muutustega. DNA metüülimise korral liidetakse DNA metüültransferaasi 
(DNMT) vahendusel metüülrühm DNA tsütosiin-guanosiin (CpG) dinukleotiid-
sele järjestusele (Holliday and Pugh, 1975; Klose and Bird, 2006). CpG 
järjestust esineb kogu genoomi ulatuses ja valdavalt on need metüülitud. CpG 
järjestused, mis asuvad geeni promootoris on metüülitud väiksemas ulatuses ja 
nende metüülimise aste korreleerub geeni repressiooniga ehk siis DNA hüper-
metüülimine pärsib transkriptsiooni reguleerivate valkude seostumist DNA-ga. 
Muutused DNA metüülimise/demetüülimise protsesside tasakaalus võivad luua 
olukorra, kus ekspresseeruvad need geenid, mis peaksid olema vaigistatud või 
vastupidi ning seeläbi võivadki tekkida püsivad geeniekspressiooni muutused, 
mis omakorda soodustavad erinevate haiguste, sealhulgas ravimsõltuvuse, teket. 
 
 
Töö eesmärgid  
Antud töö peaeesmärgiks oli hinnata DNA metüülimise rolli kokaiini poolt 
põhjustatud käitumusliku sensitisatsiooni kujunemises hiirtel ja rottidel. 
 
Täpsemad töö eesmärgid olid järgmised: 
 
1. Uurida: a) kokaiini manustamise mõju DNMT-de ja valitud markergeenide 
ekspressioonile hiirte naalduvas tuumas; ja b) hinnata DNMT inhibiitori, 
zebulariini, toimet kokaiini poolt esilekutsutud geeniekspressiooni muutustes 
ning käitumusliku sensitisatsiooni kujunemises täiskasvanud hiirtel. 
2. Hinnata metüülrühma doonor S-adenosüülmetioniini (SAM) mõju kokaiini 
poolt esilekutsutud geeniekspressiooni muutustes ja käitumusliku sensitisat-
siooni kujunemises täiskasvanud hiirtel. 
3. Selgitada, kas varajases elueas kogetud stress (maternaalse separatsiooni 
mudel, MS) võib mõjutada DNMT-de ja valitud markergeenide ekspres-
siooni noorte ja täiskasvanud rottide naalduvas tuumas ning kas need 
muutused on seotud kokaiini poolt põhjustatud käitumusliku sensitisatsiooni 
tekkega täiskasvanueas.  
 
 
Töö tulemused ja järeldused 
1. Käesoleva töö tulemused näitavad, et kokaiini manustamine suurendas 
dünaamiliselt Dnmt3a ja Dnmt3b ekspressiooni hiirte naalduvas tuumas ja 
hipokampuses, kuid ei mõjutanud oluliselt Dnmt1 ekspressiooni. Kuna on 
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leitud, et DNMT3 perekonda kuuluvad ensüümid DNMT3A ja DNMT3B 
vastutavad uute (de novo) metüülimismustrite loomise eest (Okano et al., 
1999) ja DNMT1 olemasolevate metüülimismustrite säilitamise eest (Bestor, 
2000; Goll and Bestor, 2005), siis võib järeldada, et kokaiini manustamine 
mõjutab pigem de novo DNA metüülimist. Kasutades metüülitud DNA 
immunosadestamist ja metüülspetsiifilist kvantitatiivset reaalaja PCR, 
leidsime, et nii akuutne kui ka korduv kokaiini manustamine suurendasid 
ravimsõltuvusega seotud markergeeni proteiin fosfataas 1 katalüütilise ala-
ühiku (PP1c) promootori piirkonna hüpermetüülimist hiirte naalduvas 
tuumas. PP1c promootori hüpermetüülimise tulemusena oli oluliselt vähe-
nenud PP1c ekspressioon nii mRNA kui valgu tasemel. PP1c ekspressiooni 
langus võib omakorda põhjustada häireid rakusisestes signaaliülekande 
protsessides, kuna on leitud et PP1c osaleb transkriptsioonifaktorite (nt. 
CREB), kinaaside (nt. Ca2+/kalmoduliin-sõltuv proteiin kinaas II) ja retsep-
torite (nt. AMPA retseptori alaühik GluR1) fosforüleerimise inhibeerimises 
(Genoux et al., 2002; Canettieri et al., 2003). Teiseks uuritavaks marker-
geeniks oli antud töös fosB. Erinevalt PP1c, oli fosB promootor kokaiini 
manustamise järgselt hüpometüülitud ning transkriptsioon suurenenud. Siit 
järeldub, et kokaiini manustamine võib põhjustada nii DNA metüülimist kui 
ka demetüülimist (metüülmärgiste eemaldamist geeni promootori piir-
konnast).  
DNMT inhibiitori, zebulariini, intraventrikulaarne manustamine enne 
kokaiini manustamist kõrvaldas PP1c promootori hüpermetüülimise hiirte 
naalduvas tuumas ja normaliseeris PP1c ekspressiooni. Käitumiskatsete tule-
musena leidsime, et zebulariini manustamine pidurdas kokaiini poolt põhjus-
tatud käitumusliku sensitisatsiooni väljakujunemist täiskasvanud hiirtel. 
Seega, kokaiini poolt põhjustatud muutused DNA metüülimise/ 
demetüülimise protsessides võivad olla olulised mehhanismid käitumusliku 
sensitisatisooni kujunemises ning DNMT inhibiitori manustamine võib 
normaliseerida hüpermetüülitud geenide transkriptsiooni. 
 
2. Kasutades Illumina platvormil põhinevat, kogu genoomi katvat geeni-
ekspressiooni analüüsi, leidsime, et kuigi genoomi tasemel mõjutab SAM 
vaid väheste geenide ekspressiooni, avaldab ta modifitseerivat toimet 
kokaiini poolt esilekutsutud geeniekspressiooni muutustele täiskasvanud 
hiirte naalduvas tuumas. SAM-i modifitseeriv toime avaldus ka geeni tase-
mel, kuna avastasime, et korduv SAM-i manustamine põhjustas nii hüpo- 
kui ka hüpermetüülimist Illumina ekspressioonikiibi analüüsi andmete põhjal 
valitud markergeenide promootori piirkonnas. Lisaks leidsime, et korduv 
SAM-i manustamine vähendas metüültransferaasi aktiivsust ja langetas 
Dnmt3a ja Dnmt3b ekspressiooni nii in vivo kui ka in vitro. Siit järeldub, et 
SAM-i modifitseeriv toime kokaiini poolt esilekutsutud geeniekspressiooni 
muutustele võib olla seotud DNA metüülimise/demetüülimise protsesside 
tasakaalu muutustega hiirte naalduvas tuumas. Käitumiskatsete tulemused 
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näitasid, et SAM ise ei suurenda hiirte lokomotoorset aktiivsust. SAM + 
kokaiini koosmanustamise katsetes (SAM-i manustati hiirtele 20 minutit 
enne kokaiini süstimist) aga leidsime, et SAM suurendab kokaiini poolt 
põhjustatud lokomotoorse aktiivsuse tõusu nii käitumusliku sensitisatisooni 
induktsiooni- kui ka ekspressioonifaasis. Seega, metüülrühma doonor SAM 
avaldab modifitseerivat toimet kokaiini poolt esilekutsutud geeniekspres-
siooni muutustele naalduvas tuumas ning soodustab käitumusliku sensitisat-
siooni teket täiskasvanud hiirtel. 
 
3. Varajases elueas kogetud stressi modelleerimiseks kasutasime MS mudelit, 
mille korral rotipojad eraldati emast esimesel kahel elunädalal (postnataalsed 
päevad PND1-14) iga päev 180-ks minutiks. Töö tulemused näitasid, et MS 
põhjustas püsivaid muutuseid DNMT-de ja valitud markergeenide 
(PP1c ja A2AR) ekspressioonis rottide naalduvas tuumas. Kuna leid-
sime, et MS põhjustas globaalselt DNA hüpometüülimist ning PP1c ja 
A2AR promootorite hüpermetüülimist, siis oletame, et MS võib reguleerida 
DNA metüülimist nii globaalselt kui ka geeni spetsiifiliselt. Käitumiskatsete 
tulemused näitasid, et MS suurendas nii täiskasvanud rottide uudistamis- kui 
ka lokomotoorset aktiivsust. Antud töö tulemuste põhjal saab järeldada, et 
MS võib DNA metüülimise kaudu põhjustada püsivaid muutuseid 
geeniekspressioonis ning luua tausta, mis soodustab kokaiini poolt 
põhjustatud käitumusliku sensitisatsiooni teket täiskasvanueas.  
 
Seega, käesoleva töö tulemused näitavad, et DNA metüülimine mängib olulist 
rolli kokaiini poolt põhjustatud käitumusliku sensitisatsiooni kujunemises. 
Veelgi enam, keskkonnategurid nagu SAM ja varajases elueas kogetud stress, 
võivad DNA metüülimise kaudu soodustada psühhostimulaatoritest tingitud 
ravimsõltuvuse teket nii hiirtel kui ka rottidel.  
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